

# CITATION REPORT

List of articles citing

The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation

DOI: 10.1056/nejm199011293232201

New England Journal of Medicine, 1990, 323, 1505-11.

**Source:** <https://exaly.com/paper-pdf/21563451/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1487	Atrial fibrillation--risk marker for stroke. <i>New England Journal of Medicine</i> , <b>1990</b> , 323, 1556-8	59.2	105
1486	Should patients with lone atrial fibrillation be treated with anticoagulant therapy. <b>1991</b> , 18, 301-2		2
1485	Strokes soon after oral anticoagulant therapy in patients with atrial fibrillation. <b>1991</b> , 338, 1158		
1484	Safety of DMPA. <b>1991</b> , 338, 1157-8		6
1483	Prevention of embolic complications in nonvalvular atrial fibrillation in the elderly. <b>1991</b> , 1, 458-66		3
1482	Antiplatelet therapy in the prevention of stroke. <b>1991</b> , 42 Suppl 5, 39-50		3
1481	Stroke Prevention in Atrial Fibrillation Study. Final results. <b>1991</b> , 84, 527-39		1479
1480	Risk factors for stroke in patients with nonrheumatic atrial fibrillation: a case-control study. <b>1991</b> , 91, 156-61		112
1479	Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. <b>1991</b> , 18, 349-55		964
1478	Seminars in thrombosis, thrombolysis and vascular biology. 3. Platelet activity in cardiovascular disease. <b>1991</b> , 79, 49-63		8
1477	"Heartstart" Scotland. <i>BMJ: British Medical Journal</i> , <b>1991</b> , 303, 364-5		5
1476	Sexual behaviour in Scottish prisons.. <b>1991</b> , 303, 364-364		
1475	4. Natural history. <b>1991</b> , 154, 747-751		
1474	Secondary Stroke Prevention. <b>1991</b> , 2, 517-527		2
1473	Narrow Complex Tachycardias: Differential Diagnosis and Management. <b>1991</b> , 9, 619-640		3
1472	Drugs, HIV, and prisons. <b>1991</b> , 303, 363-364		
1471	Sexual behaviour in Scottish prisons. <b>1991</b> , 303, 364-364		4

1470 New deal for old hearts. *BMJ: British Medical Journal*, **1991**, 303, 364

1469 Atrial fibrillation: new findings about an old nemesis. **1991**, 26, 75-8, 81-2, 85-8

1468 Nihilism and stroke therapy. **1991**, 22, 1105-7

36

1467 Using anticoagulants safely. Guidelines for therapeutic and prophylactic regimens. **1991**, 90, 121-2, 127-32

2

1466 Cardioembolic stroke. Primary and secondary prevention. **1991**, 90, 67-72, 77

4

1465 A Review of Surgery for Atrial Fibrillation. **1991**, 2, 541-561

22

1464 Stroke prevention in nonvalvular atrial fibrillation. **1991**, 115, 727-36

40

1463 Stroke prevention in nonvalvular atrial fibrillation: a review of prospective randomized trials. **1991**, 30, 511-8

98

1462 Prevention of embolism in atrial fibrillation. **1991**, vmr-2, 111-119

1461 Nonrheumatic atrial fibrillation. Risk of stroke and role of antithrombotic therapy. **1991**, 84, 469-81

173

1460 The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. *New England Journal of Medicine*, **1991**, 325, 129-32

59.2 9

1459 Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. **1991**, 22, 983-8

5193

1458 Oral anticoagulant drugs. *New England Journal of Medicine*, **1991**, 324, 1865-75

59.2 481

1457 The Impact of Long-term Warfarin Therapy on Quality of Life. **1991**, 151, 1944

91

1456 Stroke prevention in atrial fibrillation trial. **1991**, 84, 933-5

24

1455 Oral Anticoagulants. **1992**, 102, 312S-326S

10

1454 Aspirin and Other Platelet-Active Drugs. **1992**, 102, 327S-336S

18

1453 Hemorrhagic complications of anticoagulant treatment. **1992**, 102, 352S-363S

103

1452	Antithrombotic therapy for venous thromboembolic disease. <b>1992</b> , 102, 408S-425S		66
1451	Antithrombotic therapy in valvular heart disease. <b>1992</b> , 102, 434S-444S		25
1450	Review: atrial fibrillation and stroke prevention. <b>1992</b> , 21, 374-80		4
1449	Randomized trials of warfarin for atrial fibrillation. <i>New England Journal of Medicine</i> , <b>1992</b> , 327, 1451-3	59.2	38
1448	Mitral annular calcification and the risk of stroke in an elderly cohort. <i>New England Journal of Medicine</i> , <b>1992</b> , 327, 374-9	59.2	318
1447	Carotid endarterectomy. <i>New England Journal of Medicine</i> , <b>1992</b> , 326, 762-3; author reply 764	59.2	
1446	Comparison of markers of coagulation activation in patients under oral anticoagulation at different levels. <b>1992</b> , 30, 461-6		
1445	Non-rheumatic atrial fibrillation: warfarin or aspirin for all?. <b>1992</b> , 68, 544-7; discussion 547-8		4
1444	Recent advances in cerebrovascular disease. <b>1992</b> , 2, 187-206		2
1443	Government. <i>JAMA - Journal of the American Medical Association</i> , <b>1992</b> , 268, 362		27.4
1442	Cardiac disease. <b>1992</b> , 2, 207-226		1
1441	Oral anticoagulant therapy. Urgent need for standardization. <b>1992</b> , 86, 1332-5		15
1440	Evolving Strategies for the Management of Atrial Fibrillation. <i>JAMA - Journal of the American Medical Association</i> , <b>1992</b> , 267, 3332	27.4	4
1439	Accuracy and Precision of a Portable Anticoagulation Monitor in a Clinical Setting. <b>1992</b> , 152, 589		36
1438	Treatment of chronic nonvalvular atrial fibrillation in the elderly: a decision analysis. <b>1992</b> , 12, 239-49		59
1437	Management of atrial fibrillation. <i>New England Journal of Medicine</i> , <b>1992</b> , 326, 1264-71	59.2	231
1436	Geriatric Medicine. <i>JAMA - Journal of the American Medical Association</i> , <b>1992</b> , 268, 360		27.4
1435	Antithrombotic therapy in atrial fibrillation. <b>1992</b> , 102, 426S-433S		156

1434	Elderly subjects aged 70 years and above have different risk factors for ischemic and hemorrhagic strokes compared to younger subjects. <b>1992</b> , 40, 124-9	19
1433	Left atrial size in paroxysmal atrial fibrillation: echocardiographic evaluation and follow-up. <b>1992</b> , 80, 89-93	12
1432	Decision analytic and cost-effectiveness issues concerning anticoagulant prophylaxis in heart disease. <b>1992</b> , 102, 538S-549S	26
1431	Atrial fibrillation and stroke: prevalence in different types of stroke and influence on early and long term prognosis (Oxfordshire community stroke project). <i>BMJ: British Medical Journal</i> , <b>1992</b> , 305, 1460-5	175
1430	Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk. The Stroke Prevention in Atrial Fibrillation Investigators. <b>1992</b> , 116, 6-12	463
1429	Emergency reversal of anticoagulation after intracerebral hemorrhage. <b>1992</b> , 23, 972-7	256
1428	Current concepts in anticoagulation. <b>1992</b> , 27, 187-94, 199-200	
1427	How to avert impending stroke. <b>1992</b> , 92, 221-8, 231, 234	1
1426	Oral anticoagulant therapy. Newer indications and an improved method of monitoring. <b>1992</b> , 91, 285-8, 293-6	11
1425	TIA and minor stroke. How to identify and treat patients at risk for recurrent cerebral ischemia. <b>1992</b> , 91, 197-202, 211	1
1424	Antithrombotic treatment and atrial fibrillation. <i>BMJ: British Medical Journal</i> , <b>1992</b> , 305, 1445-6	32
1423	Oral anticoagulants: pharmacodynamics, clinical indications and adverse effects. <b>1992</b> , 32, 196-209	69
1422	Adverse reactions as a cause of hospital admission in the aged. <b>1992</b> , 2, 356-67	93
1421	Sinus node disease. Current concepts in diagnosis and therapy. <b>1992</b> , 44, 728-37	11
1420	Cost-effective intervention in stroke. <b>1992</b> , 2, 468-99	20
1419	Antiplatelet and anticoagulant drugs in coronary vascular disease. <b>1992</b> , 2, 529-42	4
1418	Cardiogenic embolism to the brain. <b>1992</b> , 339, 589-94	147
1417	Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. <i>New England Journal of Medicine</i> , <b>1992</b> , 327, 1406-12	59.2 1114

1416	Thromboembolism in nonvalvular atrial fibrillation: the answer may be in the ventricle. <b>1992</b> , 37, 277-82	9
1415	The effect of aspirin on the risk of stroke in patients with nonrheumatic atrial fibrillation: The BAATAF Study. <b>1992</b> , 124, 1567-73	62
1414	Risk factors for systemic embolism in patients with paroxysmal atrial fibrillation. <b>1992</b> , 124, 149-53	45
1413	Assessment of the efficacy and safety of antiarrhythmic therapy for chronic atrial fibrillation: observations on the role of trial design and implications of drug-related mortality. <b>1992</b> , 124, 924-32	45
1412	Risk factors for stroke in nonrheumatic atrial fibrillation. <b>1992</b> , 92, 709-10	
1411	The reply. <b>1992</b> , 92, 709-710	
1410	Predictors of thromboembolism in atrial fibrillation: I. Clinical features of patients at risk. The Stroke Prevention in Atrial Fibrillation Investigators. <b>1992</b> , 116, 1-5	396
1409	Cost effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective. <i>BMJ: British Medical Journal</i> , <b>1992</b> , 305, 1457-60	90
1408	Echocardiographic findings and the increased risk of stroke in nonvalvular atrial fibrillation. <b>1992</b> , 81, 189-95	13
1407	Warfarin Compared to Aspirin for Prevention of Arterial Thromboembolism in Atrial Fibrillation. <b>1992</b> , 2, 332-341	11
1406	Considerations for Using Lower Doses of Warfarin. <b>1992</b> , 6, 1105-1114	5
1405	Rationale for Antithrombotic Therapy in Atrial Fibrillation. <b>1992</b> , 10, 253-269	2
1404	Low-dose amiodarone for atrial fibrillation: time for a prospective study?. <b>1992</b> , 116, 1017-20	43
1403	Atrial fibrillation: epidemiology and the risk and prevention of stroke. <b>1992</b> , 15, 1332-46	21
1402	Incidence and prognostic significance of chronic atrial fibrillation among 5,839 consecutive patients with acute myocardial infarction. The SPRINT Study Group. Secondary Prevention Reinfarction Israeli Nifedipine Trial. <b>1992</b> , 70, 816-8	23
1401	Frequency of thromboembolic stroke in persons greater than or equal to 60 years of age with extracranial carotid arterial disease and/or mitral annular calcium. <b>1992</b> , 70, 123-4	19
1400	Rationale and design for the Asymptomatic Carotid Artery Plaque Study (ACAPS). The ACAPS Group. <b>1992</b> , 13, 293-314	59
1399	Current therapy for supraventricular tachycardia. <b>1992</b> , 17, 411-77	8

1398	Therapeutic ranges for oral anticoagulation in different thromboembolic disorders. <b>1992</b> , 64, 52-9	4
1397	Therapeutic target values in oral anticoagulation--justification of Dutch policy and a warning against the so-called moderate-intensity regimens. <b>1992</b> , 64, 60-5	36
1396	Left atrial thrombi in non-rheumatic atrial fibrillation: assessment of prevalence by transesophageal echocardiography. <b>1993</b> , 9, 65-72	24
1395	Mitral valve disease. <b>1993</b> , 18, 425-478	1
1394	Atrial fibrillation: new management strategies. <b>1993</b> , 18, 235-300	6
1393	Usefulness of transesophageal echocardiography in unexplained cerebral ischemia. <b>1993</b> , 72, 1448-52	42
1392	Delayed restoration of atrial function after conversion of atrial flutter by pacing or electrical cardioversion. <b>1993</b> , 71, 63-7	50
1391	Low-dose amiodarone for atrial fibrillation. <b>1993</b> , 72, 75F-81F	51
1390	Proportional hazards (Cox) regression. <b>1993</b> , 8, 702-11	65
1389	Zur Frage der Adjuvanten Medikamentösen Therapie des Venenbypasses. <b>1993</b> , 25, 298-301	1
1388	Lone atrial fibrillation and anticoagulant therapy. <b>1993</b> , 16, 504-6	4
1387	Stroke and atrial fibrillation: to anticoagulate or not. <b>1993</b> , 16, 529-30	1
1386	Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. <b>1993</b> , 95, 315-28	698
1385	Cox/maze procedure for atrial septal defect with atrial fibrillation: management strategies. <b>1993</b> , 55, 607-10	62
1384	Five-year experience with the maze procedure for atrial fibrillation. <b>1993</b> , 56, 814-823; discussion 823-4	393
1383	The decline in stroke mortality. An epidemiologic perspective. <b>1993</b> , 3, 571-5	18
1382	Platelet function, thrombin and fibrinolytic activity in patients with heart failure. <b>1993</b> , 14, 205-12	178
1381	Bleeding Complications in Oral Anticoagulant Therapy. <b>1993</b> , 153, 1557	327

1380	Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group. <b>1993</b> , 118, 511-20	481
1379	Adverse effects of coumarin anticoagulants. <b>1993</b> , 9, 263-71	17
1378	Prophylaxis and treatment of stroke. The state of the art in 1993. <b>1993</b> , 45, 329-37	15
1377	Overview of the randomized trials to prevent stroke in atrial fibrillation. <b>1993</b> , 3, 563-7	22
1376	Impact of transesophageal echocardiogram on the management of acute stroke. <b>1993</b> , 3, 57-60	3
1375	From The Lancet The case of Dr John Henderson Bell. <b>1993</b> , 341, 1322	
1374	Atrial fibrillation: Current understandings and research imperatives. <b>1993</b> , 22, 1830-1834	104
1373	Atrial arrhythmias. <b>1993</b> , 341, 1317-22	119
1372	Warfarin in chronic atrial fibrillation. <b>1993</b> , 341, 1376-7	10
1371	Atrial fibrillation and anticoagulation: from randomised trials to practice. <b>1993</b> , 341, 1381-4	35
1370	Immunologically complex kidneys. <b>1993</b> , 342, 1250-1	1
1369	Anticoagulants for atrial fibrillation. <b>1993</b> , 342, 1251-2	9
1368	Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. <b>1993</b> , 342, 1255-1262	1527
1367	Transoesophageal echocardiography in the investigation of stroke: experience in 135 patients with cerebral ischaemic events. <b>1993</b> , 23, 477-83	12
1366	Warfarin: is it time to reduce target ranges again?. <b>1993</b> , 23, 692-6	4
1365	Cardiogenic thromboembolism: review of clinical trials. <b>1993</b> , 4, 9-11	
1364	Oral Anticoagulant Therapy 50 Years Later. <b>1993</b> , 153, 586	34
1363	Lewis A. Conner Lecture. Contributions of epidemiology to the prevention of stroke. <b>1993</b> , 88, 2471-8	24



- 1362 Treatment of atrial fibrillation. Recommendations from a workshop arranged by the Medical Products Agency (Uppsala, Sweden) and the Swedish Society of Cardiology. **1993**, 14, 1427-33 13
- 1361 Warfarin in the Prevention of Stroke Associated with Nonrheumatic Atrial Fibrillation. *New England Journal of Medicine*, **1993**, 328, 1041-1043 59.2 1
- 1360 Current management of ischaemic stroke. **1993**, 56, 6-16 29
- 1359 The risk of emergency intestinal bleeding among users of acenocoumarin: a population-based cohort study. **1993**, 44, 85-92 8
- 1358 Aspirin as a therapeutic agent in cardiovascular disease. Special Writing Group. **1993**, 87, 659-75 200
- 1357 Anticoagulation in patients with atrial fibrillation. Doctors reluctant despite evidence. *BMJ: British Medical Journal*, **1993**, 307, 1494 4
- 1356 The geriatric "medical and public health" imperative revisited. **1993**, 41, 78-84 14
- 1355 Recent developments in primary prevention of stroke. **1993**, 38, S6-7
- 1354 Anticoagulation in patients with atrial fibrillation. Not safe and not cheap. *BMJ: British Medical Journal*, **1993**, 307, 1492 2
- 1353 Familial Sick Sinus Disease: Another Mendelian Etiology of Stroke. **1993**, 3, 120-122
- 1352 Stroke prophylaxis: hypertension management and antithrombotic therapy. **1993**, 27, 471-9 5
- 1351 Controversies in stroke: past and present. The Willis Lecture. **1993**, 24, 1251-8 29
- 1350 Silent infarcts in patients with ischemic stroke are related to age and size of the left atrium. **1993**, 24, 1347-51 48
- 1349 Indobufen in the prevention of thromboembolic complications in patients with heart disease. A randomized, placebo-controlled, double-blind study. **1993**, 87, 162-4 49
- 1348 The use of expected value as an aid to decisions regarding anticoagulation in patients with atrial fibrillation. **1993**, 24, 2128-34 7
- 1347 Left atrial spontaneous contrast echoes--markers of thromboembolic risk in patients with atrial fibrillation. **1993**, 14, 326-35 43
- 1346 Echocardiography in the evaluation of cardiac sources of emboli: the role of transthoracic echocardiography. **1993**, 10, 373-96 3
- 1345 Antithrombotic Therapy in Atrial Fibrillation-To the Editor. **1993**, 104, 1939-1940

1344	Platelet aggregation in patients with atrial fibrillation taking aspirin or warfarin. <b>1993</b> , 24, 1458-61	45
1343	Informed consent in clinical trials. ... it's the law. <i>BMJ: British Medical Journal</i> , <b>1993</b> , 307, 1494-5	
1342	Anticoagulation in patients with atrial fibrillation. Underuse of warfarin is multifactorial. <i>BMJ: British Medical Journal</i> , <b>1993</b> , 307, 1492-3	6
1341	Anticoagulation for atrial fibrillation and stroke prevention. <b>1993</b> , 12, 280-4	6
1340	The Stroke Prevention Patient Outcomes Research Team. Goals and methods. <b>1993</b> , 24, 2135-42	25
1339	Stroke Management. <b>1993</b> , 6, 297-303	
1338	Informed consent in clinical trials. Should be comprehensive. <i>BMJ: British Medical Journal</i> , <b>1993</b> , 307, 1494	4
1337	Anticoagulation in patients with atrial fibrillation. Don't deny treatment to elderly people. <i>BMJ: British Medical Journal</i> , <b>1993</b> , 307, 1493-4	
1336	Anticoagulation in patients with atrial fibrillation. Atrial fibrillation associated with aging. <i>BMJ: British Medical Journal</i> , <b>1993</b> , 307, 1494	6
1335	Heart disease in patients with stroke: incidence, impact, and implications for rehabilitation. Part 1: Classification and prevalence. <b>1993</b> , 74, 752-60	136
1334	Current Status of Carotid Endarterectomy. <b>1993</b> , vmr-4, 243-258	3
1333	Cardiac Arrhythmias: Syncope and Stroke. <b>1993</b> , 11, 375-390	8
1332	Initial experience with the maze procedure for atrial fibrillation. <b>1993</b> , 105, 1077-1087	65
1331	Bleeding Complications in the Patient with Cardiac Disease Following Thrombolytic and Anticoagulant Therapies. <b>1993</b> , 5, 511-523	3
1330	Preventing Systemic Embolism in Patients with Abnormal Ventricular Function. <b>1994</b> , 12, 477-485	1
1329	Managing chronic atrial fibrillation: a Markov decision analysis comparing warfarin, quinidine, and low-dose amiodarone. <b>1994</b> , 120, 449-57	52
1328	Nonvalvular Atrial Fibrillation and Stroke. <b>1994</b> , 180-187	
1327	Antithrombotic therapy prescribed for patients with non-rheumatic atrial fibrillation. <b>1994</b> , 39, 110-1	6

1326	Long-term oral anticoagulant therapy: update on indications, therapeutic ranges, and monitoring. <b>1994</b> , 307, 128-32		13
1325	Management of acute stroke. <b>1994</b> , 96, 75-85		
1324	Preventing Systemic Embolization in Patients with Atrial Fibrillation. <b>1994</b> , 12, 495-504		3
1323	Cardiac arrhythmias in elderly patients. <b>1994</b> , 4, 107-112		
1322	Management of Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , <b>1994</b> , 272, 1614	27.4	54
1321	Anticoagulation in Atrial Fibrillation. <b>1994</b> , 154, 1945		112
1320	Clinical implications of left atrial appendage flow patterns in nonrheumatic atrial fibrillation. <b>1994</b> , 105, 748-52		52
1319	Antithrombotic Therapy in Paroxysmal Atrial Fibrillation. <b>1994</b> , 105, 972		
1318	Echocardiographic predictors of nonrheumatic atrial fibrillation. The Framingham Heart Study. <b>1994</b> , 89, 724-30		770
1317	Cerebrovascular disease: a clinical approach. <b>1994</b> , 4, 289-310		
1316	Recent advances in cardiology. <b>1994</b> , 70, 257-74		
1315	Warfarin or aspirin for non-rheumatic atrial fibrillation?. <b>1994</b> , 32, 57-60		2
1314	Guide to anticoagulant therapy. Part 2: Oral anticoagulants. American Heart Association. <b>1994</b> , 89, 1469-80		164
1313	Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. <b>1994</b> , 89, 224-7		469
1312	Patient preferences for stroke outcomes. <b>1994</b> , 25, 1721-5		159
1311	The risk of embolic stroke. Another piece of the puzzle. <i>New England Journal of Medicine</i> , <b>1994</b> , 331, 1517-9	59.2	35
1310	Treatment of atrial fibrillation in a district general hospital. <b>1994</b> , 71, 92-5		81
1309	Long-term results of percutaneous aspiration embolectomy. <b>1994</b> , 17, 241-6		35

1308	The source of embolism in amaurosis fugax and retinal artery occlusion. <b>1994</b> , 18, 83-6	23
1307	Bleeding Complications to Long-Term Oral Anticoagulant Therapy. <b>1994</b> , 1, 17-25	22
1306	Spontaneous echo contrast on transthoracic echocardiography and left atrial thrombus in rheumatic mitral valve disease patients: a clinicopathologic study. <b>1994</b> , 17, 547-51	6
1305	Non-anticoagulation in atrial fibrillation. <b>1994</b> , 163, 448-50	4
1304	Hypercoagulable state under low-intensity warfarin anticoagulation assessed with hemostatic markers in cardiac disorders. <b>1994</b> , 74, 935-9	9
1303	The electrophysiologic basis, surgical development and clinical results of the maze procedure for atrial flutter and atrial fibrillation. <b>1994</b> , 10, 9-38	4
1302	A computerized intervention to improve timing of outpatient follow-up: a multicenter randomized trial in patients treated with warfarin. National Consortium of Anticoagulation Clinics. <b>1994</b> , 9, 131-9	48
1301	Anticoagulation and hemostasis in cardiac surgical patients. <b>1994</b> , 9, 443-61	4
1300	Incidence and risks associated with atrial fibrillation. <b>1994</b> , 17, 1005-10	15
1299	Anticoagulants: when and how?. <b>1994</b> , 17, 1011-5	1
1298	Initial experience with intracardiac atrial defibrillation in patients with chronic atrial fibrillation. <b>1994</b> , 17, 1067-78	99
1297	Atrial fibrillation: the next frontier. <b>1994</b> , 17, 1203-7	7
1296	Observations from intraatrial recordings on the termination of electrically induced atrial fibrillation in humans. <b>1994</b> , 17, 1231-42	30
1295	Classical anticoagulant therapy for venous thromboembolism. <b>1994</b> , 37, 59-70	5
1294	Prognostic implications of left atrial spontaneous echo contrast in nonvalvular atrial fibrillation. <b>1994</b> , 24, 755-62	292
1293	Left atrial appendage blood velocity and thromboembolic risk in patients with atrial fibrillation. <b>1994</b> , 24, 1429-30	22
1292	Relations between left atrial appendage blood flow velocity, spontaneous echocardiographic contrast and thromboembolic risk in vivo. <b>1994</b> , 23, 961-9	568
1291	Assessment of left atrial appendage function by biplane transesophageal echocardiography in patients with nonrheumatic atrial fibrillation: identification of a subgroup of patients at increased embolic risk. <b>1994</b> , 23, 599-607	275

1290	Independent Risk Factors for Atrial Fibrillation in a Population-Based Cohort. <i>JAMA - Journal of the American Medical Association</i> , <b>1994</b> , 271, 840	27.4	1763
1289	Atrial fibrillation, stroke, and antithrombotic treatment. <b>1994</b> , 127, 961-8		14
1288	Prothrombin fragment F 1 + 2 and oral anticoagulant therapy. <b>1994</b> , 75, 601-7		8
1287	Aspirin and prevention of stroke. <b>1994</b> , 343, 233-4		3
1286	Aspirin or warfarin for non-rheumatic atrial fibrillation?. <b>1994</b> , 343, 683-4		15
1285	Stroke Prevention in Atrial Fibrillation II Study. <b>1994</b> , 343, 1508-9		5
1284	Cerebrovascular espial. <b>1994</b> , 4, 46-51		6
1283	Paroxysmal atrial fibrillation in pregnancy. <b>1994</b> , 4, 170-171		
1282	Transient ischemic attack and minor ischemic stroke: an algorithm for evaluation and treatment. Mayo Clinic Division of Cerebrovascular Diseases. <b>1994</b> , 69, 1027-39		15
1281	Optimal management of older patients with atrial fibrillation. <b>1994</b> , 4, 184-93		10
1280	The treatment of atrial fibrillation. An evaluation of drug therapy, electrical modalities and therapeutic considerations. <b>1994</b> , 48, 345-71		51
1279	Risk Factors Associated with Ischaemic Stroke. <b>1994</b> , 1, 132-145		2
1278	Warfarin or Aspirin as Secondary Prevention of Ischaemic Stroke?. <b>1994</b> , 2, 341-346		
1277	Stroke prevention and AF: aspirin stakes a claim but warfarin still usual first choice. <b>1994</b> , 4, 11-13		1
1276	Transthoracic echo/Doppler in the identification of patients with chronic non-valvular atrial fibrillation at risk for thromboembolic events. <b>1994</b> , 15, 1545-51		24
1275	Interactions of warfarin with drugs and food. <b>1994</b> , 121, 676-83		371
1274	Nonvalvular atrial fibrillation and primary stroke prevention from a geriatric point of view. <b>1994</b> , 49, 86-91		
1273	Medical treatment for stroke prevention. <b>1994</b> , 121, 41-53		64

1272	Comparison of a standard and a sensitive thromboplastin in monitoring low intensity oral anticoagulant therapy. <b>1994</b> , 102, 134-7	3
1271	Stroke prevention. An opportunity for efficient utilization of health care resources during the coming decade. <b>1994</b> , 25, 220-4	86
1270	Anticoagulant and Antiplatelet Therapy in Cardioembolic Stroke. <b>1994</b> , 4, 29-33	1
1269	Prevention of Cerebrovascular Ischemic Events with Antiplatelet Drugs: Who Benefits Most?. <b>1994</b> , 4, 24-28	
1268	Drug and Surgical Issues in Stroke Prevention. <b>1994</b> , 4, 16-25	1
1267	Stroke: the way things really are. <b>1994</b> , 25, 1290-4	7
1266	Anticoagulants for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attacks. <b>2000</b> , CD000185	3
1265	WITHDRAWN: Antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attacks. <b>1996</b> , CD000186	2
1264	Cibenzoline versus flecainide in the prevention of paroxysmal atrial arrhythmias: a double-blind randomized study. <b>1995</b> , 35, 471-7	8
1263	Usefulness of M-mode, 2-dimensional, and Doppler echocardiography in the diagnosis, prognosis, and management of valvular aortic stenosis, aortic regurgitation, and mitral annular calcium in older patients. <b>1995</b> , 43, 295-300	1
1262	Antithrombotic therapy in atrial fibrillation. <b>1995</b> , 108, 352S-359S	186
1261	Hemorrhagic complications of anticoagulant treatment. <b>1995</b> , 108, 276S-290S	135
1260	Antithrombotic therapy in valvular heart disease. <b>1995</b> , 108, 360S-370S	20
1259	Making decisions about antithrombotic therapy in heart disease. Decision analytic and cost-effectiveness issues. <b>1995</b> , 108, 457S-470S	21
1258	Research in the Danish health service system: completeness and validity of prescription data, illustrated by analysis of utilization of oral anticoagulants. <b>1995</b> , 7, 33-41	13
1257	Randomized comparison of aspirin and phenprocoumon for prevention of right-sided thromboembolic complications associated with transvenous defibrillation leads. <b>1995</b> , 16, 986-92	8
1256	Design Considerations for the Warfarin-Antiplatelet Recurrent Stroke Study. <b>1995</b> , 5, 156-157	12
1255	Antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attacks. <b>1995</b> ,	

1254	Interaction of dietary factors with oral anticoagulants: review and applications. <b>1995</b> , 95, 580-4	44
1253	Cost-effectiveness analysis in heart disease, Part II: Preventive therapies. <b>1995</b> , 37, 243-71	53
1252	Low-intensity oral anticoagulation in sickle-cell disease reverses the prethrombotic state: promises for treatment?. <b>1995</b> , 90, 715-7	58
1251	Long-term anticoagulant therapy in cerebrovascular disease: does bleeding outweigh the benefit?. <b>1995</b> , 237, 323-9	12
1250	European Stroke Prevention Study 2: A study of low-dose acetylsalicylic acid and of high dose dipyridamole in secondary prevention of cerebro-vascular accidents. <b>1995</b> , 2, 416-24	2
1249	Quantification of blood echogenicity: evaluation of a semiquantitative method of grading spontaneous echo contrast. <b>1995</b> , 21, 1191-8	42
1248	Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulant Therapy Study (AFASAK 2): Methods and Design. <b>1995</b> , 2, 125-130	5
1247	Implantable atrial defibrillators. <b>1995</b> , 6, 634-48	19
1246	Transient ischemic attacks (TIA): current issues in diagnosis and management. <b>1995</b> , 7, 329-37	
1245	Silent cortical strokes associated with atrial fibrillation. <b>1995</b> , 18, 573-4	23
1244	Antithrombotic agents in cerebral ischemia. <b>1995</b> , 75, 34B-38B	41
1243	Suppression of plasma-activated factor VII levels by warfarin therapy. <b>1995</b> , 15, 241-6	23
1242	Atrial fibrillation and anticoagulant therapy. <b>1995</b> , 16, 302-12	25
1241	Plasma concentrations of atrial natriuretic peptide in cardioembolic stroke with atrial fibrillation. <b>1995</b> , 42, 71-7	5
1240	Guidelines for prevention of thromboembolic events in valvular heart disease. Study Group of the Working Group on Valvular Heart Disease of the European Society of Cardiology. <b>1995</b> , 16, 1320-30	122
1239	Cardiac Problems in Patients with Neurologic Disease. <b>1995</b> , 13, 179-208	20
1238	The Heart and Thyroid Disease. <b>1995</b> , 11, 219-229	29
1237	Risk Factors for Bleeding during Anticoagulation. <b>1995</b> , vnr-6, 53-63	

1236	Drugs and surgery in the prevention of ischemic stroke. <i>New England Journal of Medicine</i> , <b>1995</b> , 332, 238-48	59.2	163
1235	Value of transoesophageal echocardiography before DC cardioversion in patients with atrial fibrillation: assessment of embolic risk. <b>1995</b> , 73, 306-9		1
1234	Prevalence, Age Distribution, and Gender of Patients With Atrial Fibrillation. <b>1995</b> , 155, 469		1229
1233	Prevention of Embolic Events After Cardioversion of Atrial Fibrillation. <b>1995</b> , 155, 1353		32
1232	Treatment of Resistant Atrial Fibrillation. <b>1995</b> , 155, 1885		36
1231	Stroke prevention. <b>1995</b> , 52, 347-55		120
1230	Antiarrhythmic Prophylaxis vs Warfarin Anticoagulation to Prevent Thromboembolic Events Among Patients With Atrial Fibrillation. <b>1995</b> , 155, 913		14
1229	Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. <b>1995</b> , 108, 231S-246S		228
1228	Aspirin and other platelet-active drugs. The relationship among dose, effectiveness, and side effects. <b>1995</b> , 108, 247S-257S		73
1227	Antithrombotic therapy for venous thromboembolic disease. <b>1995</b> , 108, 335S-351S		135
1226	Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. <i>New England Journal of Medicine</i> , <b>1995</b> , 333, 5-10	59.2	379
1225	Effect of age upon the induction and maintenance of anticoagulation with warfarin. <b>1995</b> , 71, 153-5		28
1224	Cost-effectiveness of Warfarin and Aspirin for Prophylaxis of Stroke in Patients With Nonvalvular Atrial Fibrillation. <i>JAMA - Journal of the American Medical Association</i> , <b>1995</b> , 274, 1839	27.4	182
1223	Stroke prevention. <b>1995</b> , 71, 198-201		0
1222	Stroke and atrial fibrillation: risks, prevention and therapy in the elderly. <b>1995</b> , 20, 23-8		1
1221	Cumulative meta-analysis of clinical trials builds evidence for exemplary medical care. <b>1995</b> , 48, 45-57; discussion 59-60		275
1220	Management of intracranial hemorrhage associated with anticoagulant therapy. <b>1995</b> , 44, 438-42; discussion 443		109
1219	Newer developments in the management of atrial fibrillation. <b>1995</b> , 130, 1094-106		75



1218	Risk of arterial embolization in 224 patients awaiting cardiac transplantation. <b>1995</b> , 129, 564-70	56
1217	Role of transesophageal echocardiography in the detection of left atrial thrombus in patients with chronic nonrheumatic atrial fibrillation. <b>1995</b> , 130, 287-95	38
1216	Meta-analytic tools for medical decision making: a practical guide. <b>1995</b> , 15, 81-96	99
1215	Oral anticoagulant treatment in a medical care district--a descriptive study. <b>1995</b> , 13, 268-74	6
1214	Treatment of stroke in older patients. A state of the art review. <b>1995</b> , 6, 29-44	
1213	Anticoagulants in older patients. A safety perspective. <b>1995</b> , 6, 45-54	50
1212	Acute cerebral infarction. Optimal management in older patients. <b>1995</b> , 6, 445-55	4
1211	Fall-related injuries in anticoagulated stroke patients during inpatient rehabilitation. <b>1995</b> , 76, 840-3	20
1210	Bleeding and thromboembolism during anticoagulant therapy: a population-based study in Rochester, Minnesota. <b>1995</b> , 70, 725-33	230
1209	Outcomes of warfarin therapy: lessons from the real world. <b>1995</b> , 70, 806-8	12
1208	Cardiovascular disease in elderly patients. <b>1996</b> , 71, 184-96	38
1207	Left atrial spontaneous echo contrast: its prevalence and importance in patients undergoing transesophageal echocardiography and particularly those with a cerebrovascular embolic event. <b>1996</b> , 9, 62-70	14
1206	Outpatient anticoagulation issues for the primary care physician. <b>1996</b> , 80, 475-91	10
1205	The risks and costs of upper gastrointestinal disease attributable to NSAIDs. <b>1996</b> , 25, 373-96	68
1204	Transesophageal echocardiographic assessment of embolic sources: intracardiac and extracardiac masses and aortic degenerative disease. <b>1996</b> , 12, 273-94	6
1203	Embolic thrombus on mitral anulus calcification. <b>1996</b> , 9, 894-6	9
1202	Anticoagulation therapy: bleeding and thromboembolic complications. <b>1996</b> , 348, 1456-7	2
1201	Regional left atrial stasis during atrial fibrillation and flutter: determinants and relation to stroke. <b>1996</b> , 27, 1722-9	69

1200	Cardiac microembolism: prevalence and clinical outcome. <b>1996</b> , 136, 143-7	19
1199	Evolving models of warfarin management: anticoagulation clinics, patient self-monitoring, and patient self-management. <b>1996</b> , 132, 1095-100	118
1198	The management of atrial fibrillation. <b>1996</b> , 101, 413-21	29
1197	Cardioembolic stroke. <b>1996</b> , 100, 465-74	33
1196	The incidence of asymptomatic paroxysmal atrial fibrillation in patients treated with propranolol or propafenone. <b>1996</b> , 54, 207-11	35
1195	Predictors of ischemic stroke in non-rheumatic atrial fibrillation. <b>1996</b> , 56, 61-70	29
1194	Prevention of thromboembolism in patients with atrial fibrillation. <b>1996</b> , 14, 537-42	3
1193	Antiarrhythmic drug therapy in the treatment of atrial fibrillation. <b>1996</b> , 14, 507-20	15
1192	Therapeutic strategies for atrial fibrillation. The value of decision analysis. <b>1996</b> , 14, 623-40	6
1191	Current guidelines for the treatment of congestive heart failure. <b>1996</b> , 51, 89-98	14
1190	The risks and benefits of antithrombotic therapy in chronic atrial fibrillation. <b>1996</b> , 164, 624-6	3
1189	Atrial fibrillation: restoration and maintenance of sinus rhythm and indications for anticoagulation therapy. <b>1996</b> , 125, 311-23	61
1188	Should all patients with atrial fibrillation receive warfarin? Evidence from randomized clinical trials. <b>1996</b> , 17, 674-81	32
1187	The utilization of antithrombotic prophylaxis for atrial fibrillation in a geriatric rehabilitation hospital. <b>1996</b> , 44, 708-11	10
1186	The use of oral anticoagulants (warfarin) in older people. AGS Clinical Practice Committee. <b>1996</b> , 44, 1112-3	5
1185	Anti-thrombotic therapy for non-rheumatic atrial fibrillation. <b>1996</b> , 89, 409-14	4
1184	Paroxysmal atrial fibrillation: is anticoagulation justified?. <b>1996</b> , 31, 11, 15-6, 19	
1183	Prevalence of atrial fibrillation and association of atrial fibrillation with prior and new thromboembolic stroke in older patients. <b>1996</b> , 44, 521-3	65

1182	Potential cardioembolic sources in an elderly population without stroke. A transthoracic and transoesophageal echocardiographic study in randomly selected volunteers. <b>1996</b> , 17, 1103-11	19
1181	Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attacks. <b>2000</b> , CD000187	3
1180	The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. <b>1996</b> , 124, 970-9	371
1179	Transesophageal Echocardiography in the Management of Transient Ischemic Attack and Ischemic Stroke. <b>1996</b> , 6, 15-25	4
1178	Atrial fibrillation in the elderly. <b>1996</b> , 19, 765-75	23
1177	Failure to prescribe warfarin to patients with nonrheumatic atrial fibrillation. <b>1996</b> , 11, 713-20	99
1176	Why isn't warfarin prescribed to patients with nonrheumatic atrial fibrillation?. <b>1996</b> , 11, 721-8	111
1175	Should we just let the anticoagulation service do it? The conundrum of anticoagulation for atrial fibrillation. <b>1996</b> , 11, 768-70	21
1174	Familial idiopathic atrial fibrillation with bradyarrhythmia. <b>1996</b> , 155, 7-10	13
1173	Vascular dementia: persisting controversies and questions. <b>1996</b> , 3, 299-308	6
1172	Atrial fibrillation, anticoagulation, and stroke. <b>1996</b> , 77, 38A-44A	58
1171	Maintaining sinus rhythm with antifibrillatory drugs in atrial fibrillation. <b>1996</b> , 78, 67-72	4
1170	Monitoring low-dose warfarin therapy by a central laboratory and implications for clinical trials and patient care. The Coumadin Aspirin Reinfarction (CARS) Pilot Study Group. <b>1996</b> , 78, 1074-6	2
1169	Control of heart rate during transition from intravenous to oral diltiazem in atrial fibrillation or flutter. <b>1996</b> , 78, 1246-50	11
1168	Antithrombotic therapy in atrial fibrillation: a review of randomized trials with special reference to the Stroke Prevention in Atrial Fibrillation II (SPAF II) Trial. <b>1996</b> , 38, 337-42	22
1167	Current recommendations for the anticoagulation of patients with atrial fibrillation. <b>1996</b> , 39, 1-20	10
1166	Transesophageal echocardiography-guided approach to cardioversion of atrial fibrillation. <b>1996</b> , 39, 21-32	16
1165	Stratification of thromboembolic risk of atrial fibrillation by transthoracic echocardiography and transesophageal echocardiography: the relative role of left atrial appendage function, mitral valve disease, and spontaneous echocardiographic contrast. <b>1996</b> , 39, 57-68	26

1164	Risk of thromboembolism in new onset or transient atrial fibrillation. <b>1996</b> , 39, 69-80		14
1163	The causes and management of atrial fibrillation. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>1996</b> , 21, 37-43	2.2	1
1162	Workshop: Reimbursement for anticoagulation services. <b>1996</b> , 2, 301-304		
1161	Warfarin and aspirin as thromboprophylaxis in atrial fibrillation. <b>1996</b> , 41, 369-79		6
1160	Pharmacologic therapy of atrial flutter. <b>1996</b> , 7, 1008-12		8
1159	The use of antithrombotic drugs for primary and secondary prevention of ischaemic stroke. <b>1996</b> , 6, 315-323		
1158	Chronic Atrial Fibrillation. <b>1996</b> , 156, 2585		134
1157	Warfarin for Atrial Fibrillation. <b>1996</b> , 156, 1841		55
1156	Bleeding During Antithrombotic Therapy in Patients With Atrial Fibrillation. <b>1996</b> , 156, 409		236
1155	Status of Antithrombotic Therapy for Patients With Atrial Fibrillation in University Hospitals. <b>1996</b> , 156, 2311		75
1154	Atrial Fibrillation Following Coronary Artery Bypass Graft Surgery. <i>JAMA - Journal of the American Medical Association</i> , <b>1996</b> , 276, 300	27.4	461
1153	Paroxysmal Atrial Fibrillation. <b>1996</b> , 156, 362		31
1152	Routine Transesophageal Echocardiography for Cerebral Ischemia. <b>1996</b> , 156, 1719		17
1151	Regional Attitudes of Generalists, Specialists, and Subspecialists About Management of Atrial Fibrillation. <b>1996</b> , 156, 2553		43
1150	National Patterns of Warfarin Use in Atrial Fibrillation. <b>1996</b> , 156, 2537		102
1149	Length of the hospital stay for mothers and newborns. <i>New England Journal of Medicine</i> , <b>1996</b> , 334, 1134; author reply 1135	59.2	7
1148	Severe toxicity of fialuridine (FIAU). <i>New England Journal of Medicine</i> , <b>1996</b> , 334, 1135; author reply 1137-8	59.2	6
1147	Primary prevention of stroke. <i>New England Journal of Medicine</i> , <b>1996</b> , 334, 1138; author reply 1139	59.2	

1146	Computer-based patient records. <i>New England Journal of Medicine</i> , <b>1996</b> , 334, 1139; author reply 1140	59.2	1
1145	Sex and Swedish 85-year olds. <i>New England Journal of Medicine</i> , <b>1996</b> , 334, 1140-1	59.2	11
1144	An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. <i>New England Journal of Medicine</i> , <b>1996</b> , 335, 540-6	59.2	704
1143	The use of angiotensin-converting enzyme inhibitors in the treatment of heart failure in hospital practice. <b>1997</b> , 73, 409-11		11
1142	Atrial Fibrillation and Stroke Prevention With Warfarin in the Long-term Care Setting. <b>1997</b> , 157, 978		102
1141	The Efficacy of Aspirin in Patients With Atrial Fibrillation. <b>1997</b> , 157, 1237		133
1140	The surgical management of atrial fibrillation. <b>1997</b> , 48, 511-23		37
1139	Restoring Sinus Rhythm in Patients With Atrial Flutter and Fibrillation: Pharmacologic or Electrical Cardioversion?. <b>1997</b> , 2, 135-144		6
1138	Aspirin with and without Dipyridamole. <b>1997</b> , 7, 10-16		1
1137	Dalteparin in Acute Ischemic Cerebrovascular Disease: A Safety Study. <b>1997</b> , 7, 28-33		4
1136	Oral Anticoagulants for Secondary Prevention of Stroke. <b>1997</b> , 7, 24-29		8
1135	Treating the non-electrical risks of atrial fibrillation. <b>1997</b> , 18 Suppl C, C19-26		5
1134	Evidence-based medicine holds the key to the future for geriatric medicine. <b>1997</b> , 45, 1268-72		6
1133	Physician attitudes concerning warfarin for stroke prevention in atrial fibrillation: results of a survey of long-term care practitioners. <b>1997</b> , 45, 1060-5		110
1132	Letters to the Editor. <b>1997</b> , 32, 37-44		
1131	[Antithrombotic therapy after cerebral ischemia]. <b>1997</b> , 65, 425-34		9
1130	Echocardiographic identification of cardiovascular sources of emboli to guide clinical management of stroke: a cost-effectiveness analysis. <b>1997</b> , 127, 775-87		81
1129	Embolic brain infarction in nonrheumatic atrial fibrillation: a clinicopathologic study in the elderly. <b>1997</b> , 48, 1593-7		22

1128	Primary stroke prevention in nonvalvular atrial fibrillation: implementing the clinical trial findings. <b>1997</b> , 31, 1187-96	16
1127	Cardioversion guided by transesophageal echocardiography: the ACUTE Pilot Study. A randomized, controlled trial. Assessment of Cardioversion Using Transesophageal Echocardiography. <b>1997</b> , 126, 200-9	158
1126	Cost considerations in the pharmacological prevention and treatment of stroke. <b>1997</b> , 11, 408-18	6
1125	Consensus guidelines for coordinated outpatient oral anticoagulation therapy management. Anticoagulation Guidelines Task Force. <b>1997</b> , 31, 604-15	100
1124	The medical management of atrial fibrillation. <b>1997</b> , 15, 689-719	12
1123	The maze procedure for cure of atrial fibrillation. <b>1997</b> , 15, 739-48	46
1122	Trends and future developments in the pharmacological treatment of acute ischaemic stroke. <b>1997</b> , 54, 9-38	50
1121	Post-Stroke Management. <b>1997</b> , 2, 30-36	
1120	Prescribing patterns for nursing home residents in the US. The reality and the vision. <b>1997</b> , 11, 255-60	25
1119	Pharmacological management of arrhythmias in the elderly. <b>1997</b> , 11, 96-110	7
1118	Is anticoagulation therapy underused in elderly patients with atrial fibrillation?. <b>1997</b> , 10, 174-84	13
1117	Determinants of compliance with anticoagulation: A case-control study. <b>1997</b> , 103, 11-7	205
1116	Stroke prevention in patients with non-valvular atrial fibrillation: a current community perspective. <b>1997</b> , 4, 320-5	5
1115	Atrial fibrillation. <b>1997</b> , 350, 943-50	71
1114	Cost-effectiveness of transesophageal echocardiographic-guided cardioversion: a decision analytic model for patients admitted to the hospital with atrial fibrillation. <b>1997</b> , 29, 122-30	61
1113	Thromboembolism in chronic atrial flutter: is the risk underestimated?. <b>1997</b> , 30, 1506-11	79
1112	Antithrombotic treatment in chronic non-rheumatic atrial fibrillation. <b>1997</b> , 51, 51-6	
1111	Electrophysiological properties in patients undergoing atrial compartment operation for chronic atrial fibrillation with mitral valve disease. <b>1997</b> , 18, 1805-15	11

1110	Prevention of Primary Event. <b>1997</b> , 8, 165-178	3
1109	The Feasibility of a Collaborative Double-Blind Study Using an Anticoagulant. <b>1997</b> , 7, 100-112	57
1108	Medical and Surgical Prevention of Stroke: Experiences around the World. <b>1997</b> , 7, 22-28	30
1107	Atrial fibrillation and dilated cardiomyopathy: therapeutic strategies when sinus rhythm cannot be maintained. <b>1997</b> , 20, 720-5	8
1106	Risk of complications of atrial fibrillation. <b>1997</b> , 20, 2684-91	19
1105	Pharmacologic management of atrial fibrillation. <b>1997</b> , 8, 818-29	7
1104	Transthoracic Versus Transesophageal Two-Dimensional Echo Doppler Determination of Flow Velocity in the Left Atrial Appendage. <b>1997</b> , 14, 357-362	10
1103	Risk of thromboembolism in chronic atrial flutter. <b>1997</b> , 79, 1043-7	83
1102	Possible association of thrombotic, nonbacterial vegetations of the mitral ring-mitral annular calcium and stroke. <b>1997</b> , 79, 1712-5	30
1101	Atrial fibrillation and stroke: elucidating a newly discovered risk factor. <b>1997</b> , 80, 11D-18D; discussion 35D-39D	11
1100	Atrial fibrillation: antiarrhythmic therapy versus rate control with antithrombotic therapy. <b>1997</b> , 80, 74G-81G	5
1099	Thromboembolic risks of left atrial thrombus detected by transesophageal echocardiogram. <b>1997</b> , 79, 626-9	95
1098	The treatment of atrial fibrillation: pharmacologic and nonpharmacologic strategies. <b>1997</b> , 22, 37-108	15
1097	Biochemical markers of coagulation activation in mitral stenosis, atrial fibrillation, and cardiomyopathy. <b>1997</b> , 20, 7-10	22
1096	Long-term management of atrial fibrillation. <b>1997</b> , 20, 381-90	5
1095	Chronic Atrial Fibrillation: Selection of Antithrombotic Therapy. <b>1997</b> , 1, 35-39	1
1094	Population pharmacokinetic-pharmacodynamic analysis of fluindione in patients. <b>1998</b> , 63, 64-78	33
1093	Spaf III Trial: Of Risk Stratification and Minimal Effective Warfarin Intensity. <b>1998</b> , 2, 44-48	

1092	Atrial fibrillation and anticoagulation in patients with permanent pacemakers: implications for stroke prevention. <b>1998</b> , 21, 1258-67	12
1091	Evolution and revolution in drug labeling: regulation of antiarrhythmic drugs by the Food and Drug Administration 1962-1996. <b>1998</b> , 21, 1457-69	5
1090	Congestive cardiac failure (CCF) as a cause of fatal stroke and all cause death. <b>1998</b> , 28, 799-804	9
1089	Association of mitral annular calcium with new thromboembolic stroke at 44-month follow-up of 2,148 persons, mean age 81 years. <b>1998</b> , 81, 105-6	32
1088	Association between mitral annular calcium and aortic atheroma as detected by transesophageal echocardiographic study. <b>1998</b> , 81, 784-6	43
1087	Impact of managed care on the treatment of atrial fibrillation. <b>1998</b> , 81, 30C-34C	4
1086	Anticoagulation to prevent stroke in atrial fibrillation and its implications for managed care. <b>1998</b> , 81, 35C-40C	15
1085	Risk factors for new thromboembolic stroke in patients > or = 62 years of age with chronic atrial fibrillation. <b>1998</b> , 82, 119-21	59
1084	Effectiveness of fixed minidose warfarin in the prevention of thromboembolism and vascular death in nonrheumatic atrial fibrillation. <b>1998</b> , 82, 433-7	92
1083	Risk of thromboembolic events in patients with atrial flutter. <b>1998</b> , 82, 580-3	97
1082	Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. <b>1998</b> , 82, 2N-9N	1541
1081	Mitral annular calcium detected by transthoracic echocardiography is a marker for high prevalence and severity of coronary artery disease in patients undergoing coronary angiography. <b>1998</b> , 82, 1183-6	94
1080	Etiology and complications of atrial fibrillation: insights from pathology studies. <b>1998</b> , 82, 10N-17N	59
1079	Long-term antithrombotic treatment for atrial fibrillation. <b>1998</b> , 82, 37N-42N	13
1078	Heart failure in thyrotoxicosis, an approach to management. <b>1998</b> , 46, 421-4	16
1077	Guidelines on oral anticoagulation: third edition. <b>1998</b> , 101, 374-87	337
1076	Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. <b>1998</b> , 352, 1167-71	323
1075	Modern management of prosthetic valve anticoagulation. <b>1998</b> , 73, 665-80	53



1074	Thrombosis and cerebrovascular disease. <b>1998</b> , 82, 523-44	4
1073	Aging and cerebrovascular disease. <b>1998</b> , 16, 687-711	30
1072	Evaluation and management of atrial fibrillation in the emergency department. <b>1998</b> , 16, 389-403	21
1071	Economic Impact of Stroke and Implications for Interventions. <b>1998</b> , 9, 19-39	2
1070	Treatment strategies for atrial fibrillation. <b>1998</b> , 104, 272-86	58
1069	Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. <b>1998</b> , 105, 91-9	611
1068	Antiplatelet therapy. Aspirin, ticlopidine/clopidogrel, and anti-integrin agents. <b>1998</b> , 12, 1231-49, vi	10
1067	Plant Secondary Metabolism. <b>1998</b> ,	201
1066	Prevention of stroke in patients with nonvalvular atrial fibrillation. <b>1998</b> , 51, 674-81	129
1065	Central role of echocardiography in the diagnosis and assessment of heart failure. British Society of Echocardiography. <b>1998</b> , 80 Suppl 1, S1-5	86
1064	Preoperative predictors of recurrent atrial fibrillation late after successful mitral valve reconstruction. <b>1998</b> , 13, 619-24	6
1063	Thrombosis and Hemostasis in Cardiology: Review of Pathophysiology and Clinical Practice (Part I). <b>1998</b> , 4, 51-75	0
1062	Screening for atrial fibrillation in primary care. <b>1998</b> , 79, 50-5	63
1061	Update on Atrial Fibrillation: Restoration of Sinus Rhythm or Ventricular Rate Control?. <b>1998</b> , 3, 185-194	1
1060	Anticoagulation for prevention of stroke. <b>1998</b> , 51, S20-2	15
1059	Stroke Prevention in Patients With Atrial Fibrillation: What Have We Learned?. <b>1998</b> , 3, 85-90	1
1058	Initiation of Warfarin Treatment in Outpatients with Nonrheumatic Atrial Fibrillation: A Scheme for Early Indication of Maintenance Dose. <b>1998</b> , 4, 274-276	6
1057	Stroke risk factors and stroke prevention. <b>1998</b> , 18, 429-40	83

1056	Atrial fibrillation: current knowledge and recommendations for management. Working Group on Arrhythmias of the European Society of Cardiology. <b>1998</b> , 19, 1294-320	194
1055	Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation. <b>1998</b> , 29, 1083-91	87
1054	Platelet-active drugs: the relationships among dose, effectiveness, and side effects. <b>1998</b> , 114, 470S-488S	139
1053	Hemorrhagic complications of anticoagulant treatment. <b>1998</b> , 114, 511S-523S	122
1052	Antithrombotic therapy for venous thromboembolic disease. <b>1998</b> , 114, 561S-578S	170
1051	Antithrombotic therapy in atrial fibrillation. <b>1998</b> , 114, 579S-589S	241
1050	Making decisions about antithrombotic therapy in heart disease: decision analytic and cost-effectiveness issues. <b>1998</b> , 114, 699S-714S	41
1049	The effect of age and quality of life on doctors' decisions to anticoagulate patients with atrial fibrillation. <b>1998</b> , 27, 285-289	7
1048	Atrial fibrillation and thromboembolism. <b>1998</b> , 87, 217-23	
1047	Recognition and Management of Cardiac Arrhythmias: Part I. General Principles and Supraventricular Tachyarrhythmias. <i>Journal of Intensive Care Medicine</i> , <b>1998</b> , 13, 15-31	33
1046	Controversies surrounding long-term anticoagulation of very elderly patients in atrial fibrillation. <b>1998</b> , 113, 1115-8	19
1045	Antithrombotic therapy in valvular heart disease. <b>1998</b> , 114, 590S-601S	26
1044	Recent national patterns of warfarin use in atrial fibrillation. <b>1998</b> , 97, 1231-3	186
1043	Cost-effectiveness of anticoagulation in nonrheumatic atrial fibrillation in the primary prevention of ischemic stroke. <b>1998</b> , 29, 1827-32	62
1042	Association between mitral annulus calcification and carotid atherosclerotic disease. <b>1998</b> , 29, 1833-7	80
1041	Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. <b>1998</b> , 158, 1513-21	204
1040	Atrial Fibrillation and Thromboembolism. <b>1998</b> , 87, 217-223	2
1039	Cost-effectiveness of therapies for patients with nonvalvular atrial fibrillation. <b>1998</b> , 158, 1669-77	49

1038	Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. <b>1998</b> , 114, 445S-469S	358
1037	Thromboembolic complication in atrial fibrillation in a long-term follow-up--the relationship with underlying disease, type of atrial fibrillation, and antithrombotic therapy. <b>1998</b> , 62, 255-60	5
1036	A guide to oral anticoagulant therapy. Italian Federation of Anticoagulation Clinics. <b>1998</b> , 28 Suppl 1, 1-46	5
1035	Generic warfarin: a cost-effective alternative to brand-name drug or a clinical wild card?. <b>1998</b> , 113, 261-3	14
1034	ASHP therapeutic position statement on antithrombotic therapy in chronic atrial fibrillation. American Society of Health-System Pharmacists. <b>1998</b> , 55, 376-81	6
1033	Stroke prevention and intervention. New options for improved outcomes. <b>1998</b> , 103, 43-5, 49-50, 56-8 passim	13
1032	Temporal trends in the use of anticoagulants among older adults with atrial fibrillation. <b>1999</b> , 159, 1574-8	85
1031	Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention. <b>1999</b> , 131, 688-95	179
1030	Stroke Prevention. <b>1999</b> , 10, 827-838	1
1029	Review of the Fifth American College of Chest Physicians Consensus Conference on Antithrombotic Therapy: outpatient management for adults. <b>1999</b> , 56, 1505-14	26
1028	Antithrombotic Management of Atrial Fibrillation for Stroke Prevention in Older People. <b>1999</b> , 15, 645-662	2
1027	Anticoagulation after Artificial Valve Replacement with or without Atrial Fibrillation: How Much Is Really Needed?. <b>1999</b> , 82, 130-135	3
1026	Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. <b>2000</b> , CD001927	12
1025	Anticoagulant treatment of patients with atrial fibrillation in primary health care. <b>1999</b> , 17, 59-63	7
1024	Importance of left atrial appendage flow as a predictor of thromboembolic events in patients with atrial fibrillation. <b>1999</b> , 20, 979-85	109
1023	Decrease in mortality in patients with a hospital diagnosis of atrial fibrillation in Denmark during the period 1980-1993. <b>1999</b> , 20, 1592-9	39
1022	Age-related differences in management of heart disease: a study of cardiac medication use in an older cohort. Pacemaker Selection in the Elderly (PASE) Investigators. <b>1999</b> , 47, 145-50	24
1021	The overdosed patient and bleedings with oral anticoagulation. <b>1999</b> , 25, 85-8	13

1020	Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study. <i>Atrial Fibrillation Aspirin and Anticoagulation</i> . <b>1999</b> , 159, 1322-8	158
1019	Arterial thromboembolism in patients with sick sinus syndrome: prediction from pacing mode, atrial fibrillation, and echocardiographic findings. <b>1999</b> , 81, 412-8	18
1018	Lone atrial fibrillation in elderly persons: a marker for cardiovascular risk. <b>1999</b> , 159, 1118-22	71
1017	Identification and treatment of patients with atrial fibrillation in primary care. <b>1999</b> , 81, 333-4	1
1016	Abnormalities in liver function and coagulation profile following the Fontan procedure. <b>1999</b> , 82, 40-6	100
1015	Pharmacotherapy of atrial fibrillation. <b>1999</b> , 1, 81-96	4
1014	Atrial fibrillation and its relationship to dental care. <b>1999</b> , 130, 1080-5	7
1013	Fortnightly review: anticoagulation in heart disease. <i>BMJ: British Medical Journal</i> , <b>1999</b> , 318, 238-44	15
1012	Oral anticoagulation in nonvalvular atrial fibrillation. <b>1999</b> , 245, 375-81	9
1011	Non-rheumatic atrial fibrillation and stroke. <b>1999</b> , 29, 467-72	2
1010	Atrial fibrillation: prevalence and management in an acute general medical unit. <b>1999</b> , 29, 51-8	26
1009	The role of nonpharmacologic therapies for the treatment of atrial fibrillation. <b>1999</b> , 10, 450-60; quiz 488-94	13
1008	Antithrombotic therapy in nonrheumatic/nonvalvular atrial fibrillation. <b>1999</b> , 10, 461-71	3
1007	Chronic and paroxysmal atrial fibrillation: course, prognosis, and stroke risk. <b>1999</b> , 7, 7-11	4
1006	Risk factors for stroke and primary prevention of stroke in atrial fibrillation. <b>1999</b> , 7, 21-6	2
1005	Very low-intensity antithrombotic therapy in atrial fibrillation. <b>1999</b> , 7, 67-71	2
1004	Idiopathic atrial fibrillation: prevalence, course, treatment, and prognosis. <b>1999</b> , 7, 27-31	9
1003	Management of atrial fibrillation: out-of-hospital approach. <b>1999</b> , 7, 131-5	1

1002	Secondary stroke prevention in atrial fibrillation: indications, risks, and benefits. <b>1999</b> , 7, 61-5	3
1001	Long-term anticoagulation therapy for atrial fibrillation in elderly patients: efficacy, risk, and current patterns of use. <b>1999</b> , 7, 157-63	24
1000	Outcome of valve repair and the Cox maze procedure for mitral regurgitation and associated atrial fibrillation. <b>1999</b> , 118, 628-35	138
999	Impact of the maze procedure on the stroke rate in patients with atrial fibrillation. <b>1999</b> , 118, 833-40	274
998	Primary prevention of arterial thromboembolism in nonrheumatic atrial fibrillation: the PATAF trial study design. <b>1999</b> , 20, 386-93	8
997	PERIOPERATIVE APPROACH TO THE ANTICOAGULATED PATIENT. <b>1999</b> , 17, 813-830	
996	Safety of treatment with oral anticoagulants in the elderly. A systematic review. <b>1999</b> , 14, 303-12	75
995	Epidemiology of adverse drug reactions in the elderly by drug class. <b>1999</b> , 14, 231-9	79
994	Cardioversion in patients with atrial fibrillation and left atrial thrombi on initial transesophageal echocardiography: should transesophageal echocardiography be repeated before elective cardioversion? A cost-effectiveness analysis. <b>1999</b> , 12, 508-16	17
993	Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. <b>1999</b> , 131, 492-501	1088
992	Underutilization of antithrombotic therapy in elderly rural patients with atrial fibrillation. <b>1999</b> , 137, 307-12	66
991	The use of prothrombin complex concentrates in the treatment of hemorrhages induced by oral anticoagulation. <b>1999</b> , 95, S57-61	31
990	The older man's heart and heart disease. <b>1999</b> , 83, 1291-303	11
989	Atrial fibrillation in the elderly. <b>1999</b> , 17, 173-88, ix-x	13
988	[Practice guidelines of the Spanish Society of Cardiology. Recommendations for the use of antithrombotic treatment in cardiology]. <b>1999</b> , 52, 801-20	19
987	Guidelines for stroke prevention in patients with atrial fibrillation. <b>1999</b> , 58, 997-1009	15
986	Outcomes of Long-Term Anticoagulation in Frail Elderly Patients with Atrial Fibrillation. <b>1999</b> , 17, 483-488	5
985	Lone atrial fibrillation: epidemiology and natural history. <b>1999</b> , 137, 592-5	20

984	Lone atrial fibrillation: prognostic differences between paroxysmal and chronic forms after 10 years of follow-up. <b>1999</b> , 137, 686-91	81
983	Oral anticoagulation in patients with atrial fibrillation: adherence with guidelines in an elderly cohort. <b>1999</b> , 106, 165-71	87
982	Cost-effectiveness of cardioversion and antiarrhythmic therapy in nonvalvular atrial fibrillation. <b>1999</b> , 130, 625-36	46
981	Left atrial size and the risk of ischemic stroke in an ethnically mixed population. <b>1999</b> , 30, 2019-24	190
980	The influence of randomized trials on the use of anticoagulants for atrial fibrillation. <b>1999</b> , 28, 441-6	8
979	Management of the older person with atrial fibrillation. <b>1999</b> , 47, 740-8	20
978	Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. <b>1999</b> , 131, 927-34	432
977	Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin. <i>BMJ: British Medical Journal</i> , <b>1999</b> , 319, 958-64	141
976	Preventing stroke in patients with atrial fibrillation. <i>JAMA - Journal of the American Medical Association</i> , <b>1999</b> , 281, 1830-5	27.4 101
975	Improving management of atrial fibrillation and anticoagulation in a community hospital. <b>2000</b> , 26, 18-28	15
974	Can Warfarin Randomized Trials Be Reproduced in Real Life? <b>2000</b> , 93, 58-61	2
973	Prediction of embolism in atrial fibrillation: classification of left atrial thrombi by transesophageal echocardiography. <b>2000</b> , 64, 411-5	30
972	Prevalence and clinical characteristics of patients with atrial fibrillation: analysis of 20,000 cases in Japan. <b>2000</b> , 64, 653-8	60
971	Anticoagulation for heart failure in sinus rhythm. <b>2001</b> , CD003336	3
970	Which acute stroke patients with atrial fibrillation are prescribed warfarin therapy? Results from one-year's experience in Dundee. <b>2000</b> , 45, 110-2	1
969	Anticoagulant use in nonvalvular atrial fibrillation. Determining risk and choosing the safest course. <b>2000</b> , 108, 113-6, 119-21, 125-6	4
968	The use of oral anticoagulants (warfarin) in older people. AGS Clinical Practices Committee. American Geriatric Society. <b>2000</b> , 48, 224-7	25
967	Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation. <b>2000</b> , 31, 822-7	253

966	Warfarin for stroke prevention still underused in atrial fibrillation: patterns of omission. <b>2000</b> , 31, 1217-22	99
965	Prediction of fluidione maintenance dosage hampered by large intraindividual variability. <b>2000</b> , 22, 668-75	4
964	Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation : a multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolic Secondary Prevention Cooperative Study Group. <b>2000</b> , 31, 817-21	230
963	Clinical implication of antiembolic trials in atrial fibrillation and role of transesophageal echocardiography in atrial fibrillation. <b>2000</b> , 15, 58-63	3
962	Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness. <i>BMJ: British Medical Journal</i> , <b>2000</b> , 320, 1236-9	100
961	The cost-effectiveness of different management strategies for patients on chronic warfarin therapy. <b>2000</b> , 15, 31-7	70
960	Prevention of thromboembolism in atrial fibrillation. A meta-analysis of trials of anticoagulants and antiplatelet drugs. <b>2000</b> , 15, 56-67	96
959	Role of transthoracic echocardiography in atrial fibrillation. <b>2000</b> , 17, 357-64	17
958	Transesophageal echocardiography risk factors for stroke in nonvalvular atrial fibrillation. <b>2000</b> , 17, 365-72	13
957	Risk of thromboembolism in acute atrial fibrillation or atrial flutter. <b>2000</b> , 17, 393-405	24
956	Anticoagulation and minor oral surgery: should the anticoagulation regimen be altered?. <b>2000</b> , 58, 131-5; discussion 135-6	102
955	Adequacy of anticoagulation in patients with atrial fibrillation coming to a hospital. <b>2000</b> , 20, 1060-5	52
954	The prevalence and prognostic significance of electrocardiographic abnormalities. <b>2000</b> , 25, 1-72	69
953	Atrial fibrillation: Epidemiology, mechanisms, and management. <b>2000</b> , 25, 413-524	12
952	Frequency of anticoagulation for atrial fibrillation and reasons for its non-use at a Veterans Affairs medical center. <b>2000</b> , 85, 568-72	66
951	Association of mitral annular calcium with prior thromboembolic stroke in older White, African-American, and Hispanic men and women. <b>2000</b> , 85, 672-3, A11	2
950	Risk factors for thromboembolism in patients with paroxysmal atrial fibrillation. <b>2000</b> , 86, 852-5	40
949	Anticoagulation clinics and patient self-testing for patients on chronic warfarin therapy: A cost-effectiveness analysis. <b>2000</b> , 9 Suppl 1, S13-9	31

948	Anticoagulation therapy for atrial fibrillation and coronary disease. <b>2000</b> , 9 Suppl 1, S47-51	1
947	Relationship between test frequency and outcomes of anticoagulation: a literature review and commentary with implications for the design of randomized trials of patient self-management. <b>2000</b> , 9, 283-92	111
946	Cardiomyopathy and embolization: risks and benefits of anticoagulation in sinus rhythm. <b>2000</b> , 2, 106-11	3
945	Stroke prevention in atrial fibrillation. <b>2000</b> , 2, 51-5	20
944	Antithrombotic therapy for valve disease: native and prosthetic valves. <b>2000</b> , 2, 56-60	2
943	The potential use of decision analysis to support shared decision making in the face of uncertainty: the example of atrial fibrillation and warfarin anticoagulation. <b>2000</b> , 9, 238-44	25
942	Evaluating quality of care for patients with heart failure. <b>2000</b> , 101, E122-40	101
941	Effect and outcomes of the ASGE guidelines on the perendoscopic management of patients who take anticoagulants. <b>2000</b> , 95, 1717-24	31
940	Transoesophageal echocardiography-guided cardioversion of atrial fibrillation or flutter. Selection of a low-risk group for immediate cardioversion. <b>2000</b> , 21, 837-47	44
939	Anticoagulants. <b>2000</b> , 56, 501-9	2
938	Advances in Therapy and the Management of Antithrombotic Drugs for Venous Thromboembolism. <b>2000</b> , 266-284	17
937	Why do patients with atrial fibrillation not receive warfarin?. <b>2000</b> , 160, 41-6	410
936	Arrhythmia Therapy in the Elderly. <b>2000</b> , 9, 151-158	
935	Stroke prevention as an indication for the Maze procedure in the treatment of atrial fibrillation. <b>2000</b> , 12, 56-62	40
934	Cox-Maze procedure for atrial fibrillation: Mayo Clinic experience. <b>2000</b> , 12, 30-7	179
933	Stroke: management and rehabilitation. Part III of III. <b>2000</b> , 51, 977-84	3
932	The quality of anticoagulation management. <b>2000</b> , 160, 895-6	13
931	Troglitazone as an anti-inflammatory agent. <b>2000</b> , 160, 3004	0



930	Donepezil (Aricept <sup>®</sup> ) treatment of multi infarct dementia: The caregivers and clinical impression. <b>2000</b> , 15, 201-211	4
929	Appropriate outcome measures in trials evaluating treatment of atrial fibrillation. <b>2000</b> , 139, 752-60	12
928	Patent foramen ovale diameter and embolic stroke: a part of the puzzle?. <b>2000</b> , 109, 506-7	8
927	Mild mitral regurgitation was associated with increased prevalence of thromboembolic events in patients with nonrheumatic atrial fibrillation. <b>2000</b> , 72, 229-33	17
926	Influence of atrial fibrillation on the morbido-mortality of patients on hemodialysis. <b>2000</b> , 140, 886-90	126
925	Atrial fibrillation after cardiac operation: risks, mechanisms, and treatment. <b>2000</b> , 69, 300-6	150
924	Decision analysis and guidelines for anticoagulant therapy to prevent stroke in patients with atrial fibrillation. <b>2000</b> , 355, 956-62	144
923	Diagnosis and treatment of nonsteroidal anti-inflammatory drug-associated upper gastrointestinal toxicity. <b>2000</b> , 29, 97-124, vi	32
922	Use of oral anticoagulants in older patients. <b>2000</b> , 16, 409-35	29
921	Cost effectiveness of therapies for atrial fibrillation. A review. <b>2000</b> , 18, 317-33	7
920	[Prevention of thromboembolic disease in patients with heart disease]. <b>2000</b> , 26, 293-7	0
919	Clinical trials of pacing mode selection. <b>2000</b> , 18, 1-23, vii	18
918	Management of arrhythmias. <b>2000</b> , 16, 593-618	5
917	Utilizaci3n del tratamiento anticoagulante en los pacientes con fibrilaci3n auricular no reum3tica. <b>2000</b> , 53, 200-204	6
916	Association between mitral annulus calcification and aortic atheroma: a prospective transesophageal echocardiographic study. <b>2000</b> , 152, 451-6	49
915	Heparin and oral anticoagulants in the treatment of brain ischemia. <b>2000</b> , 173, 3-9	18
914	Treatment of underlying atrial fibrillation: paced rhythm obscures recognition. <b>2000</b> , 36, 784-7	25
913	Epidemiology and natural history of atrial fibrillation: clinical implications. <b>2001</b> , 37, 371-8	575

912	ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients with Atrial Fibrillation)	54
911	ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients with Atrial Fibrillation)	634
910	A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. <i>New England Journal of Medicine</i> , <b>2001</b> , 345, 1444-51	59.2 916
909	Early cardioversion of atrial fibrillation facilitated by transesophageal echocardiography: short-term safety and impact on maintenance of sinus rhythm at 1 year. <b>2001</b> , 110, 694-702	64
908	Pharmacologic management of atrial fibrillation: current therapeutic strategies. <b>2001</b> , 141, S15-21	31
907	Evolving role of echocardiography in the management of atrial fibrillation. <b>2001</b> , 141, 518-27	5
906	[Evidence based medical treatment of heart failure]. <b>2001</b> , 54, 715-34	6
905	[New concepts on the treatment of atrial fibrillation]. <b>2001</b> , 117, 427-37	0
904	Guías de práctica clínica de la Sociedad Española de Cardiología en arritmias cardíacas. <b>2001</b> , 54, 307-367	31
903	Hemorrhagic complications of oral anticoagulant therapy. <b>2001</b> , 17, 49-56	23
902	Antithrombotic therapy in atrial fibrillation. <b>2001</b> , 17, 131-47	13
901	Evidence-based treatment of patients with ischemic cerebrovascular disease. <b>2001</b> , 19, 79-105	6
900	Antiplatelet therapy in the elderly. Aspirin, ticlopidine-clopidogrel, and GPIIb/GPIIIa antagonists. <b>2001</b> , 17, 31-48	8
899	Secondary prevention of stroke in patients with nonvalvular atrial fibrillation: optimal intensity of anticoagulation. <b>2001</b> , 15, 623-31	9
898	Antithrombotic therapy in cerebrovascular disease. <b>2001</b> , 437-457	
897	ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients with Atrial Fibrillation)	747
896	A benefit/risk analysis of the prevention of brain ischaemia with anticoagulant drugs: when, how and whom to treat?. <b>2001</b> , 11 Suppl 1, 100-4	
895	Underutilization of anticoagulation therapy in chronic atrial fibrillation. <b>2001</b> , 42, 55-65	13

894	Oral Anticoagulant Therapy in Patients with Nonrheumatic Atrial Fibrillation and Risk of Bleeding. <b>2001</b> , 85, 418-422	123
893	Non-valvular atrial fibrillation and stroke prevention. National Blood Pressure Advisory Committee of the National Heart Foundation. <b>2001</b> , 174, 234-9	41
892	Stroke prophylaxis in nonvalvular atrial fibrillation. <b>2001</b> , 14, 59-65	1
891	Anticoagulation in the elderly. <b>2001</b> , 7, 365-70	10
890	The ten most commonly asked questions about stroke prevention in atrial fibrillation. <b>2001</b> , 9, 187-92	1
889	Anticoagulation in the Ambulatory Patient: Basic Principles and Current Concepts in Warfarin Therapy. <b>2001</b> , 17, 18-37	2
888	Platelet-active drugs : the relationships among dose, effectiveness, and side effects. <b>2001</b> , 119, 39S-63S	380
887	Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation. <b>2001</b> , 40, 1183-8	181
886	Instability of anticoagulation intensity contributes to occurrence of ischemic stroke in patients with non-rheumatic atrial fibrillation. <b>2001</b> , 65, 404-8	17
885	Cost-Effectiveness of antiarrhythmic drugs for prevention of thromboembolism in patients with paroxysmal atrial fibrillation. <b>2001</b> , 65, 765-8	4
884	Antithrombotic therapy in atrial fibrillation. <b>2001</b> , 119, 194S-206S	363
883	Managing oral anticoagulant therapy. <b>2001</b> , 119, 22S-38S	436
882	Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter. <b>2001</b> , CD001938	16
881	Antithrombotic therapy in valvular heart disease. <b>2001</b> , 119, 207S-219S	48
880	Are the results of randomized controlled trials on anticoagulation in patients with atrial fibrillation generalizable to clinical practice?. <b>2001</b> , 161, 1443-7	83
879	A Survey of Long-Term Antiarrhythmic Therapy in Elderly Patients with Atrial Fibrillation. <b>2001</b> , 31, 93-97	3
878	Should stroke subtype influence anticoagulation decisions to prevent recurrence in stroke patients with atrial fibrillation?. <b>2001</b> , 32, 2828-32	73
877	Paroxysmal atrial fibrillation. <b>2001</b> , 94, 665-78	46

876	Evaluation of risk factors for stroke/embolism and of complications due to anticoagulant therapy in atrial fibrillation. <b>2001</b> , 32, 2246-52	57
875	Atrial fibrillation and stroke : concepts and controversies. <b>2001</b> , 32, 803-8	260
874	Clinical correlates and drug treatment of residents with stroke in long-term care. <b>2001</b> , 32, 1385-93	65
873	Oral anticoagulant treatment in very elderly patients with atrial fibrillation. <b>2001</b> , 27, 7-10	2
872	Choices in medical management for prevention of acute ischemic stroke. <b>2001</b> , 1, 33-8	3
871	Stroke prevention in atrial fibrillation: physicians' attitudes to anticoagulation in older people. <b>2001</b> , 33, 219-26	23
870	Primary stroke prevention. <b>2001</b> , 8, 1-15	23
869	Low adjusted-dose acenocoumarol therapy in sickle cell disease: a pilot study. <b>2001</b> , 68, 179-83	31
868	Special Considerations for the Elderly Patient with Atrial Fibrillation. <b>2001</b> , 5, 243-253	
867	What's the Best Drug for Maintaining Sinus Rhythm?. <b>2001</b> , 5, 222-225	
866	Association of mitral annular calcium with symptomatic peripheral arterial disease in older persons. <b>2001</b> , 88, 333-4	23
865	An evidence-based review of the resting electrocardiogram as a screening technique for heart disease. <b>2001</b> , 44, 55-67	50
864	Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting. <b>2001</b> , 161, 2458-63	139
863	Association between mitral annular calcification and carotid atheroma. <b>2001</b> , 52, 201-4	10
862	Oral anticoagulation and hemorrhagic complications in an elderly population with atrial fibrillation. <b>2001</b> , 161, 2125-8	78
861	Thromboembolic risk in atrial flutter. The FLASIEC (Flutter Atriale Societ^ Italiana di Ecografia Cardiovascolare) multicentre study. <b>2001</b> , 22, 1042-51	38
860	Prevention of cerebral thromboembolism by low-dose anticoagulant therapy in atrial fibrillation with mitral regurgitation. <b>2001</b> , 37, 422-6	11
859	Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. <b>2001</b> , 119, 8S-21S	770

858	Hemorrhagic complications of anticoagulant treatment. <b>2001</b> , 119, 1085-1215		415
857	[Atrial fibrillation--treatment]. <b>2001</b> , 126, 1472-5		0
856	ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. <b>2001</b> , 22, 1852-923		307
855	Exercise tolerance and quality of life in elderly patients with chronic atrial fibrillation. <b>2001</b> , 6, 23-9		52
854	Management of haemorrhagic complications associated with oral anticoagulant treatment. <b>2002</b> , 1, 129-36		8
853	Heart-brain relationship: atrial fibrillation and stroke. <b>2002</b> , 24, 493-9		7
852	Management of the older person with atrial fibrillation. <b>2002</b> , 57, M352-63		34
851	Effects of anticoagulation on infarct size and clinical outcome in acute cardioembolic stroke. <b>2002</b> , 53, 551-6		22
850	Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , <b>2002</b> , 288, 2441-8	27.4	508
849	Atrial fibrillation. <b>2002</b> , 4, 91-101		11
848	Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial. <b>2002</b> , 113, 42-51		118
847	A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. <b>2002</b> , 113, 359-64		1087
846	Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. <b>2002</b> , 39, 301-7		261
845	Benefits, morbidity, and mortality associated with long-term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: a prospective randomized study. <b>2002</b> , 35, 413-21		156
844	Atrial fibrillation in the elderly: facts and management. <b>2002</b> , 19, 819-46		47
843	Prospective evaluation of the quality of oral anticoagulation management in an outpatient clinic and in general practices. <b>2002</b> , 105, 103-8		9
842	Management of atrial fibrillation after cardiac surgery-part II: prevention and treatment. <b>2002</b> , 16, 626-37		13
841	The morbidity related to atrial fibrillation at a tertiary centre in one year: 9.0% of all strokes are potentially preventable. <b>2002</b> , 9, 268-72		23

840	Baseline characteristics of patients with atrial fibrillation: the AFFIRM Study. <b>2002</b> , 143, 991-1001	120
839	[Anticoagulation in permanent atrial fibrillation after 75 years of age]. <b>2002</b> , 23, 834-9	2
838	Trends in case-fatality in 22968 patients admitted for the first time with atrial fibrillation in Scotland, 1986-1995. <b>2002</b> , 82, 229-36	31
837	[The efficacy of scheduled cardioversion in atrial fibrillation. Comparison of two schemes of treatment: electrical versus pharmacological cardioversion]. <b>2002</b> , 55, 113-20	12
836	La fibrilaci3n auricular permanente en las enfermedades cardiovasculares en Espa2a. Estudio CARDIOTENS 1999. <b>2002</b> , 55, 943-952	45
835	[Oral anticoagulation treatment in patients with non-valvular auricular fibrillation]. <b>2002</b> , 30, 284-9	1
834	Cambios en el perfil cl3nico de los pacientes anticoagulados durante la d3cada de los noventa. <b>2002</b> , 55, 55-60	6
833	Spontaneous intracerebral hemorrhage: epidemiology and clinical presentation. <b>2002</b> , 13, 265-79, v	73
832	Principles of drug therapy in older patients: rational drug prescribing. <b>2002</b> , 18, 577-92	48
831	[Antithrombotic treatment in hypertensive patients with chronic atrial fibrillation. CARDIOTENS 99 study]. <b>2002</b> , 118, 327-31	8
830	Adverse events in the use of HeartMate vented electric and Novacor left ventricular assist devices: comparing apples and oranges. <b>2002</b> , 124, 1063-7	19
829	Impact of Cox maze procedure on outcome in patients with atrial fibrillation and mitral valve disease. <b>2002</b> , 124, 575-83	145
828	Onderzoek in de huisartsgeneeskunde, de rol van academische netwerkenhuisartsgeneeskunde onderzoek wetenschappelijk onderzoek. <b>2002</b> , 45, 305-309	
827	[Prevention of arterial thromboembolisms in patients with atrial fibrillation]. <b>2002</b> , 27, 322-8	
826	Atrial fibrillation or flutter and stroke: a Danish population-based study of the effectiveness of oral anticoagulation in clinical practice. <b>2002</b> , 252, 64-9	29
825	Deciding on anticoagulating the oldest old with atrial fibrillation: insights from cost-effectiveness analysis. <b>2002</b> , 50, 863-9	32
824	The impact of age on antithrombotic use in elderly patients with non-valvular atrial fibrillation. <b>2002</b> , 21, 36-41	24
823	Anticoagulants for atrial fibrillation: why is the treatment rate so low?. <b>2002</b> , 25, 447-54	57

822	Anti-thrombotic strategies for patients with atrial fibrillation and heart failure. <b>2002</b> , 7, 261-6	3
821	Problems, interventions and complications in long-term oral anticoagulation therapy. <b>2002</b> , 14, 65-72	5
820	Age and first INR after initiation of oral anticoagulant therapy with acenocoumarol predict the maintenance dosage. <b>2003</b> , 15, 197-203	6
819	Physicians' attitudes and the use of oral anticoagulants: surveying the present and envisioning future. <b>2003</b> , 16, 33-7	8
818	Pharmacologic management of atrial fibrillation in the elderly: rate control, rhythm control, and anticoagulation. <b>2003</b> , 5, 380-6	1
817	Oral anticoagulants vs. aspirin for stroke prevention in patients with non-valvular atrial fibrillation: the verdict is in. <b>2003</b> , 7, 374-8	6
816	Do anticoagulation management services improve care? Implications of the Managing Anticoagulation Services Trial. <b>2003</b> , 7, 379-81	12
815	Use of subcutaneous enoxaparin compared to intravenous heparin and oral phenprocoumon in the setting of cardioversion—the ACE study (Anticoagulation in Cardioversion using Enoxaparin). <b>2003</b> , 7, 382-6	
814	The long-term outcome of patients with coronary disease and atrial fibrillation undergoing the Cox maze procedure. <b>2003</b> , 126, 2016-21	155
813	[Anticoagulant treatment in atrial fibrillation]. <b>2003</b> , 52, 272-9	0
812	Diabetic atrial fibrillation patients: mortality and risk for stroke or embolism during a 10-year follow-up. <b>2003</b> , 19, 320-8	32
811	Iatrogenic complications and risks of nerve conduction studies and needle electromyography. <b>2003</b> , 27, 517-26	79
810	Physician compliance with outpatient oral anticoagulant guidelines in Auvergne, France. <b>2003</b> , 18, 903-7	8
809	Combined antiplatelet therapy in atrial fibrillation: review of the literature and future avenues. <b>2003</b> , 14, S60-3	27
808	Prevention of vascular events in patients with atrial fibrillation: evidence, guidelines, and practice. <b>2003</b> , 14, S52-5	6
807	[Use of oral anticoagulants in patients discharged with atrial fibrillation in 2000]. <b>2003</b> , 56, 1057-63	4
806	Coumarin therapy in thrombosis. <b>2003</b> , 17, 201-16, viii	13
805	[A prospective protocol increases oral anticoagulant prescription in patients with chronic, nonvalvular atrial fibrillation]. <b>2003</b> , 56, 971-7	3

804	[Use of anticoagulation at the time of discharge in patients with heart failure and atrial fibrillation]. <b>2003</b> , 56, 880-7	3
803	[Identification of factors responsible for oral over-anticoagulation in outpatients with heart disease]. <b>2003</b> , 56, 65-72	4
802	[Image techniques for the evaluation and clinical decision making of patients with stroke]. <b>2003</b> , 56, 1119-32	2
801	Choice of prosthetic heart valve for adult patients. <b>2003</b> , 41, 893-904	218
800	Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study. <b>2003</b> , 41, 1445-51	167
799	American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. <b>2003</b> , 41, 1633-52	264
798	Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). <b>2003</b> , 146, 431-8	180
797	Tissue factor expression in atrial endothelia associated with nonvalvular atrial fibrillation: possible involvement in intracardiac thrombogenesis. <b>2003</b> , 111, 137-42	135
796	Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. <b>2003</b> , 362, 1691-8	676
795	Ought dialysis patients with atrial fibrillation be treated with oral anticoagulants?. <b>2003</b> , 87, 135-9; discussion 139-41	61
794	Preventing stroke in patients with atrial fibrillation: current treatments and new concepts. <b>2003</b> , 145, 418-23	24
793	Changing trends of antithrombotic therapy in atrial fibrillation. <b>2003</b> , 32, 236-8	
792	Evaluation of Anticoagulation Therapy in an Academic Nursing Home. <b>2003</b> , 19, 141-145	3
791	American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. <b>2003</b> , 107, 1692-711	427
790	Primary and secondary stroke prevention in nonrheumatic atrial fibrillation by oral anticoagulation. <b>2003</b> , 50, 127-35	4
789	Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. <b>2003</b> , 108, 711-6	424
788	Pharmacotherapy of atrial fibrillation. <b>2003</b> , 11, 364-74	2
787	Rising rates of hospital admissions for atrial fibrillation. <b>2003</b> , 14, 666-72	214



786	Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?. <i>JAMA - Journal of the American Medical Association</i> , <b>2003</b> , 290, 2685-92	27.4	510
785	Anticoagulation in the elderly. <b>2003</b> , 12, 243-50		14
784	Oral anticoagulant therapy in patients with atrial fibrillation. <b>2003</b> , 3, 333-8		1
783	Anticoagulation in atrial fibrillation: what is certain and what is to come. <i>European Heart Journal Supplements</i> , <b>2003</b> , 5, H45-H50	1.5	3
782	Surgical management of atrial tachyarrhythmias associated with congenital cardiac anomalies: Mayo Clinic experience. <b>2003</b> , 6, 59-71		19
781	Anticoagulation management strategies in patients with atrial fibrillation. <b>2003</b> , 2, 178-87		
780	Predictors of warfarin use among Ohio medicaid patients with new-onset nonvalvular atrial fibrillation. <b>2003</b> , 163, 1705-10		55
779	Embolitic attack in patients with atrial fibrillation and atrial thrombus depends on the character of the thrombus. <b>2003</b> , 67, 203-8		13
778	Prevention of thromboembolism in patients with mitral stenosis and associated atrial fibrillation: effectiveness of low intensity (INR target 2) oral anticoagulant treatment. <b>2003</b> , 89, 760-764		15
777	Brain Embolism. <b>2003</b> , 373-391		
776	Low-dose warfarin in atrial fibrillation leads to more thromboembolic events without reducing major bleeding when compared to adjusted-dose--a meta-analysis. <b>2004</b> , 91, 394-402		29
775	Warfarin for non-rheumatic atrial fibrillation: five year experience in a district general hospital. <b>2004</b> , 90, 1259-62		19
774	Cardiac tumour in a neonate with left ventricular outflow tract obstruction. <b>2004</b> , 90, 881		2
773	Establishing an optimal therapeutic range for coumarins: filling in the gaps. <b>2004</b> , 164, 588-90		4
772	Cost-effectiveness of a community-based screening programme for chronic atrial fibrillation in Japan. <b>2004</b> , 11, 97-102		21
771	Role of oral anticoagulation in management of atrial fibrillation. <b>2004</b> , 90, 813-7		25
770	Control of heart rate versus rhythm in rheumatic atrial fibrillation: a randomized study. <b>2004</b> , 9, 65-73		66
769	The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. <b>2004</b> , 164, 880-4		461

768	The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. <b>2004</b> , 126, 204S-233S	852
767	Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. <b>2004</b> , 126, 1938-45	228
766	Antithrombotic therapy in valvular heart disease--native and prosthetic: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. <b>2004</b> , 126, 457S-482S	267
765	Recent trials in atrial fibrillation: lessons learned beyond rate and rhythm. <i>European Heart Journal Supplements</i> , <b>2004</b> , 6, B15-B19	1.5 1
764	Direct thrombin inhibition: a novel approach to stroke prevention in patients with atrial fibrillation. <b>2004</b> , 35, 1519-22	6
763	Rapid access arrhythmia clinic for the diagnosis and management of new arrhythmias presenting in the community: a prospective, descriptive study. <b>2004</b> , 90, 877-81	10
762	Chapter 5 Cardioembolic Stroke. <b>2004</b> , 29, 79-98	
761	Evidence-based guidelines for cardiovascular disease prevention in women. <b>2004</b> , 109, 672-93	526
760	Anticoagulation in the Elderly. <b>2004</b> , 17, 94-102	1
759	Evidence-based guidelines for cardiovascular disease prevention in women. American Heart Association scientific statement. <b>2004</b> , 24, e29-50	55
758	Between the Devil and the Deep Blue Sea--balancing the risks and potential benefits of warfarin for older people with atrial fibrillation. <b>2004</b> , 33, 544-7	5
757	Stroke prevention and atrial fibrillation: reasons leading to an inappropriate management. Main results of the SAFE II study. <b>2004</b> , 57, 798-806	74
756	Improving the outcomes of anticoagulation: an evaluation of home follow-up of warfarin initiation. <b>2004</b> , 256, 137-44	56
755	Measurement of bleeding severity: a critical review. <b>2004</b> , 44, 605-17	39
754	Atrial fibrillation and thrombosis: immunohistochemical differences between in situ and embolized thrombi. <b>2004</b> , 2, 1637-44	55
753	The impact of vitamin K-dependent factor depletion by warfarin on platelet-rich thrombosis after deep arterial injury. <b>2004</b> , 2, 1834-41	2
752	Stroke prophylaxis in institutionalized elderly patients with atrial fibrillation. <b>2004</b> , 52, 428-33	37
751	Anticoagulant use for atrial fibrillation in the elderly. <b>2004</b> , 52, 1151-6	96

750	The use of a modified sphygmomanometer to detect atrial fibrillation in outpatients. <b>2004</b> , 27, 639-43	40
749	Bleeding profiles of anticoagulants, including the novel oral direct thrombin inhibitor ximelagatran: definitions, incidence and management. <i>European Journal of Haematology</i> , <b>2004</b> , 73, 227-42	3.8 6
748	Cardioversion of atrial tachyarrhythmias: anticoagulation to reduce thromboembolic complications. <b>2004</b> , 46, 487-505	3
747	Comparison of the impact of atrial fibrillation on the risk of stroke and cardiovascular death in women versus men (The Copenhagen City Heart Study). <b>2004</b> , 94, 889-94	199
746	Warfarin and aspirin use and the predictors of major bleeding complications in atrial fibrillation (the Framingham Heart Study). <b>2004</b> , 94, 947-51	57
745	Do population studies confirm the benefit of oral anticoagulation in atrial fibrillation demonstrated in clinical trials?. <b>2004</b> , 10 Suppl 1, 9-16	7
744	Progress in practice. <b>2004</b> , 26, A1-A70	
743	The decision to anticoagulate: assessing whether benefits outweigh the risks for patients with atrial fibrillation. <b>2004</b> , 27, 313-20	5
742	Secondary stroke prevention: review of clinical trials. <b>2004</b> , 27, 1125-35	4
741	[Modern anticoagulation. Problems of the proven, hope for the new]. <b>2004</b> , 45, 717-26	4
740	The role of warfarin and aspirin in secondary prevention of stroke. <b>2004</b> , 6, 135-42	3
739	Anticoagulation for non-valvular atrial fibrillation - towards a new beginning with ximelagatran. <b>2004</b> , 5, 3	4
738	Anticoagulants for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischaemic attack. <b>2004</b> , CD000185	29
737	The increasing need for anticoagulant therapy to prevent stroke in patients with atrial fibrillation. <b>2004</b> , 79, 904-13	31
736	[Prevention of thromboembolism in patients with chronic atrial fibrillation in primary health care]. <b>2004</b> , 122, 53-6	2
735	Anticoagulation for atrial fibrillation. <b>2004</b> , 22, 47-62	9
734	[How suitable is thromboembolism prophylaxis for patients with chronic auricular fibrillation at 3 primary care centers]. <b>2004</b> , 33, 188-92	1
733	Mortality as an endpoint in atrial fibrillation. <b>2004</b> , 1, B8-18, discussion B18-9	37

732	[Anti-platelet agents in neurological practice]. <b>2004</b> , 160, 131-6	
731	[Anticoagulants for patients with chronic auricular fibrillation: when are they indicated?]. <b>2004</b> , 34, 374-8	0
730	Atrial fibrillation, stroke and anticoagulant use. <b>2004</b> , 13, 252-5	1
729	The impact of asymptomatic atrial fibrillation. <b>2004</b> , 43, 53-4	18
728	Left atrial structure and function after percutaneous left atrial appendage transcatheter occlusion (PLAATO): six-month echocardiographic follow-up. <b>2004</b> , 43, 1868-72	67
727	Evidence-based guidelines for cardiovascular disease prevention in women. <b>2004</b> , 43, 900-21	80
726	Prevention. European Stroke Initiative. <b>2004</b> , 17 Suppl 2, 15-29	42
725	Clinical practice. Newly diagnosed atrial fibrillation. <i>New England Journal of Medicine</i> , <b>2004</b> , 351, 2408-16	95
724	Complications hémorragiques liés aux anti-vitamine K chez les 75 ans et plus au service d'urgence : interférence d'un index prédictif de saignement. <b>2004</b> , 17, 15-20	
723	Antithrombotic therapy in atrial fibrillation: ximelagatran, an oral direct thrombin inhibitor. <b>2004</b> , 2, 163-74	6
722	Trends in utilization of antithrombotic therapy in patients with atrial fibrillation before stroke onset in a community-based study, from 1985 through 1997. From scientific evidence to practice. <b>2004</b> , 38, 121-8	16
721	Non-valvular atrial fibrillation and stroke: implications for nursing practice and therapeutics. <b>2004</b> , 17, 65-73	3
720	Mitral annular calcification is a predictor for incident atrial fibrillation. <b>2004</b> , 173, 291-4	73
719	Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack. <b>2004</b> , CD000187	44
718	Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. <b>2004</b> , 126, 234S-264S	494
717	Stroke medicine for the geriatrician. <b>2004</b> , 14, 175	
716	A new solution for an old problem? Effects of a nurse-led, multidisciplinary, home-based intervention on readmission and mortality in patients with chronic atrial fibrillation. <b>2004</b> , 19, 118-27	33
715	Epidemiology and economic impact of atrial fibrillation. <b>2004</b> , 19, 94-102	15

714	Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. <b>2004</b> , 126, 429S-456S	427
713	Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. <b>2004</b> , 126, 287S-310S	361
712	Effects of anticoagulation intensity on hemostatic markers in patients with non-valvular atrial fibrillation. <b>2004</b> , 68, 29-34	39
711	Attitudes of Japanese cardiologists toward anticoagulation for nonvalvular atrial fibrillation and reasons for its underuse. <b>2004</b> , 68, 417-21	37
710	Physicians' attitudes toward anticoagulant therapy in patients with chronic atrial fibrillation. <b>2004</b> , 43, 553-60	17
709	Prévention des accidents vasculaires cérébraux. <b>2004</b> , 1, 1-20	1
708	Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. <b>2005</b> , CD001927	73
707	Economic factors associated with antithrombotic treatments for stroke prevention in patients with atrial fibrillation. <b>2005</b> , 7, C41-C54	7
706	Long-term changes in coronary artery aneurysms in patients with Kawasaki disease: comparison of therapeutic regimens. <b>2005</b> , 69, 265-72	46
705	Atrial fibrillation in patients with first-ever stroke: frequency, antithrombotic treatment before the event and effect on clinical outcome. <b>2005</b> , 3, 1218-23	50
704	Psychosocial risk factors for adverse outcomes in patients with nonvalvular atrial fibrillation receiving warfarin. <b>2005</b> , 20, 1114-9	33
703	Is atrial fibrillation a genetic disease?. <b>2005</b> , 16, 553-6	24
702	Management of atrial fibrillation. <b>2005</b> , 30, 175-233	22
701	Arritmias y electrofisiología cardíaca: temas de actualidad en 2004. <b>2005</b> , 5, 55A-65A	
700	Epidemiological profile of atrial fibrillation: a contemporary perspective. <b>2005</b> , 48, 1-8	75
699	Antithrombotic therapy for stroke prevention in atrial fibrillation. <b>2005</b> , 48, 108-24	9
698	New treatment options for stroke prevention in atrial fibrillation. <b>2005</b> , 7, 341-9	
697	Concomitant drug, dietary, and lifestyle issues in patients with atrial fibrillation receiving anticoagulation therapy for stroke prophylaxis. <b>2005</b> , 7, 241-50	4

696	Atrial fibrillation and stroke: four treatment controversies. <b>2005</b> , 7, 491-8	1
695	Stroke prevention in diabetic and other high cardiovascular risk patients. <b>2005</b> , 5, 200-7	6
694	The impact of patient self-testing of prothrombin time for managing anticoagulation: rationale and design of VA Cooperative Study #481--the Home INR Study (THINRS). <b>2005</b> , 19, 163-72	20
693	Anticoagulant treatment at a specialized outpatient anticoagulant therapy unit, a descriptive study. <b>2005</b> , 3, 20	5
692	Appropriate Pharmacotherapy in Elderly Patients. <b>2005</b> , 48, 24	4
691	[Arrhythmias in the elderly population and their management]. <b>2005</b> , 42, 261-70	0
690	Preference-based antithrombotic therapy in atrial fibrillation: implications for clinical decision making. <b>2005</b> , 25, 548-59	57
689	Is rate control or rhythm control preferable in patients with atrial fibrillation? An argument for maintenance of sinus rhythm in patients with atrial fibrillation. <b>2005</b> , 111, 3150-6; discussion 3156-7	17
688	Is rate control or rhythm control preferable in patients with atrial fibrillation? Rate control is preferable to rhythm control in the majority of patients with atrial fibrillation. <b>2005</b> , 111, 3141-50; discussion 3157	26
687	Direct thrombin inhibitors: novel antithrombotics on the horizon in the thromboprophylactic management of atrial fibrillation. <b>2005</b> , 81, 370-5	1
686	Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) study. <b>2005</b> , 165, 1185-91	158
685	Prevention of stroke in patients with atrial fibrillation. <b>2005</b> , 5, 285-92	19
684	Antithrombotic therapy practices in US hospitals in an era of practice guidelines. <b>2005</b> , 165, 1458-64	123
683	Anticoagulation in nonvalvular atrial fibrillation. <b>2005</b> , 1, 373-80	1
682	Acute anticoagulation adjustment in patients with atrial fibrillation at risk for stroke: approaches, strategies, risks and benefits. <b>2005</b> , 3, 571-90	2
681	Anticoagulation for atrial fibrillation in the elderly. <b>2005</b> , 14, 81-6	5
680	The epidemiology of atrial fibrillation in elderly persons: the tip of the iceberg. <b>2005</b> , 14, 56-61	90
679	Evidence-based medicine and patient-centred medicine: the need to harmonize. <b>2005</b> , 10, 66-8	7

678	The lowest effective intensity of prophylactic anticoagulation for patients with atrial fibrillation. <b>2005</b> , 20, 114-9		20
677	Will this be the end of the anticoagulation clinic for patients with atrial fibrillation?. <b>2005</b> , 5, 405-8		2
676	Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. <i>JAMA - Journal of the American Medical Association</i> , <b>2005</b> , 293, 699-706	27.4	120
675	Time trends of ischemic stroke incidence and mortality in patients diagnosed with first atrial fibrillation in 1980 to 2000: report of a community-based study. <b>2005</b> , 36, 2362-6		82
674	Treatment patterns and real-world effectiveness of warfarin in nonvalvular atrial fibrillation within a managed care system. <b>2005</b> , 21, 1583-94		51
673	Current status of stroke prevention in patients with atrial fibrillation. <b>2005</b> , 7, C12-C18		5
672	Indication for antithrombotic therapy for atrial fibrillation: reconciling the guidelines with clinical practice. <b>2005</b> , 7, C28-C33		5
671	[Preventing cerebrovascular accidents during atrial fibrillation]. <b>2005</b> , 34, 1315-24		4
670	How many patients in atrial fibrillation admitted to an acute medical unit will benefit from oral anticoagulation? Application of the results of the major randomized controlled trials to 141 consecutive, unselected, elderly patients using a decision support computer program. <b>2005</b> , 16, 97-104		1
669	Atrial fibrillation: modern concepts and management. <b>2005</b> , 56, 475-94		12
668	Anticoagulation therapy in patients with chronic atrial fibrillation: a retrospective claims data analysis. <b>2005</b> , 21, 215-22		9
667	A Bayesian approach to evaluating net clinical benefit allowed for parameter uncertainty. <b>2005</b> , 58, 26-40		37
666	Low-intensity anticoagulation for stroke prevention in elderly patients with atrial fibrillation: efficacy and safety in actual clinical practice. <b>2005</b> , 12, 891-4		7
665	Genetic epidemiology of intracerebral hemorrhage. <b>2005</b> , 14, 239-43		9
664	Direct thrombin inhibitors: stroke prevention in atrial fibrillation and potential anti-inflammatory properties. <b>2005</b> , 149, S32-5		2
663	Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. <b>2005</b> , 118, 612-7		244
662	Cardiac Arrhythmias. <b>2005</b> , 52-92		
661	Intensive care of the acute stroke patient. <b>2005</b> , 8, 92-102		

660	Are transthoracic echocardiographic parameters associated with atrial fibrillation recurrence or stroke? Results from the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study. <b>2005</b> , 45, 2026-33	112
659	Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. <b>2005</b> , 46, 1729-36	305
658	Trials and tribulations of non-inferiority: the ximelagatran experience. <b>2005</b> , 46, 1986-95	85
657	Ximelagatran for stroke prevention in atrial fibrillation. <b>2005</b> , 3, 551-63	3
656	Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. <b>2006</b> , 367, 404-11	296
655	Effect of a US National Institutes of Health programme of clinical trials on public health and costs. <b>2006</b> , 367, 1319-27	104
654	To catch a moving target. <b>2006</b> , 3, 638-9	
653	Quality improvement case study: warfarin sodium interactions. <b>2006</b> , 7, 315-8	3
652	Antithrombotic therapy in atrial fibrillation. <b>2006</b> , 22, 155-66, x	6
651	Anticoagulation practice in cardiac electrophysiology. <b>2006</b> , 3, 372-4	3
650	Management of arrhythmias in the emergency department. <b>2006</b> , 24, 125-33, vii	8
649	Heart disease and aging. <b>2006</b> , 90, 849-62	43
648	ACC/AHA/ESC: Guías de Práctica Clínica 2006 para el manejo de pacientes con fibrilación auricular. Versión resumida. <b>2006</b> , 59, 1329.e1-1329.e64	2
647	Genomics and cardiac arrhythmias. <b>2006</b> , 47, 9-21	74
646	ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). <b>2006</b> , 48, 876-901	865
645	ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). <b>2006</b> , 48, 876-901	261
644	ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation). <b>2006</b> , 48, 876-901	530
643	Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). <b>2007</b> , 28, 88-136	889



642	How can we improve our use of oral anticoagulants?. <b>2006</b> , 119, 101-2	5
641	Intracardiac devices for stroke prevention. <b>2006</b> , 9, 42-8	3
640	Chronic subdural haematomas and anticoagulation or anti-thrombotic therapy. <b>2006</b> , 13, 823-7	121
639	Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. <b>2006</b> , 118, 321-33	174
638	WITHDRAWN: Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter. <b>2007</b> , CD001938	2
637	Causes cardiaques d'embolie c�btrale. <b>2006</b> , 3, 1-23	
636	Pharmacoeconomics of anticoagulation therapy for stroke prevention in atrial fibrillation: a review. <b>2006</b> , 4, 1180-5	23
635	Caplan's short rendition of Stroke during the 20th century: part II. <b>2006</b> , 1, 228-34	4
634	Advies voor het gebruik van antithrombotica bij oudere pati�nten met boezemfibrilleren. <b>2006</b> , 31, 138-143	
633	Monitoring anticoagulation in atrial fibrillation. <b>2006</b> , 21, 191-8	28
632	Worldwide management of oral anticoagulant therapy: the ISAM study. <b>2006</b> , 21, 73-7	96
631	T�cnicas de imagen en la insuficiencia cardiaca. <b>2006</b> , 6, 27F-45F	
630	Mixed comparison of stroke prevention treatments in individuals with nonrheumatic atrial fibrillation. <b>2006</b> , 166, 1269-75	110
629	Seasonal variation in stroke and stroke-associated mortality in patients with a hospital diagnosis of nonvalvular atrial fibrillation or flutter. A population-based study in Denmark. <b>2006</b> , 26, 220-5	20
628	Trends in risk of stroke in patients with a hospital diagnosis of nonvalvular atrial fibrillation: National Cohort Study in Denmark, 1980-2002. <b>2006</b> , 26, 212-9	30
627	Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation. <b>2006</b> , 37, 1075-80	209
626	Optimising stroke prevention in non-valvular atrial fibrillation. <b>2006</b> , 7, 2079-94	2
625	Prognosis in atrial fibrillation. <b>2006</b> , 27, 895-6	2

624	Stroke prophylaxis in atrial fibrillation: who gets it and who does not? Report from the Stockholm Cohort-study on Atrial Fibrillation (SCAF-study). <b>2006</b> , 27, 1954-64	139
623	Antithrombotic treatment is strongly underused despite reducing overall mortality among high-risk elderly patients hospitalized with atrial fibrillation. <b>2006</b> , 27, 2217-23	53
622	Anti-inflammatory effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Potential benefits for the prevention of atrial fibrillation. <b>2006</b> , 27, 2370-1; author reply 2371	1
621	Stroke prophylaxis in atrial fibrillation. <b>2006</b> , 27, 2370	2
620	Atrial fibrillation and stroke: from scientific evidence to practice. <b>2006</b> , 28, 251-7	3
619	Effect of oxolamine on anticoagulant effect of warfarin. <b>2006</b> , 63, 153-6	4
618	Evaluation of survival and ischaemic and thromboembolic event rates in patients with non-valvar atrial fibrillation in the general population when treated and untreated with warfarin. <b>2006</b> , 92, 196-200	30
617	Cross-sectional association of kidney function with valvular and annular calcification: the Framingham heart study. <b>2006</b> , 17, 521-7	125
616	Mechanisms of disease: Genetic mechanisms of atrial fibrillation. <b>2006</b> , 3, 276-82	32
615	ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation Executive Summary. <b>2006</b> , 114, 700-752	237
614	ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). <b>2006</b> , 27, 1979-2030	479
613	Brain Embolism. <b>2006</b> ,	9
612	Bringing the Benefits of Anticoagulation Management Services to the Community: Alberta Program May Serve as a Model of Care. <b>2006</b> , 139, 58-64	9
611	Influence of dementia on antithrombotic therapy prescribed before stroke in patients with atrial fibrillation. <b>2006</b> , 21, 401-7	2
610	ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. <b>2006</b> ,	1653
609	Data Monitoring in Clinical Trials. <b>2006</b> , 114, e257-354	37
608	Cardiac Arrhythmias 2005. <b>2006</b> ,	3
607	ASHP therapeutic position statement on antithrombotic therapy in chronic atrial fibrillation. <b>2007</b> , 64, 2281-91	3

606	Influence of decision aids on patient preferences for anticoagulant therapy: a randomized trial. <i>Cmaj</i> , <b>2007</b> , 176, 1583-7	3.5	49
605	Challenges of establishing new antithrombotic therapies in atrial fibrillation. <b>2007</b> , 116, 449-55		74
604	Newly detected atrial fibrillation and compliance with antithrombotic guidelines. <b>2007</b> , 167, 246-52		124
603	Age and risk of stroke in atrial fibrillation: evidence for guidelines?. <b>2007</b> , 28, 109-15		15
602	Noninvasive cardiac monitoring for detecting paroxysmal atrial fibrillation or flutter after acute ischemic stroke: a systematic review. <b>2007</b> , 38, 2935-40		262
601	Antikoagulation bei Patienten mit Vorhofflimmern - Sorgfältige Risikoabschätzung schützt vor Schlaganfall. <b>2007</b> , 33, 190-193		
600	Outcome parameters for trials in atrial fibrillation: recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association. <b>2007</b> , 9, 1006-23		197
599	Stroke and its prevention in chronic kidney disease. <b>2007</b> , 2, 1343-51		14
598	Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). <i>European Heart Journal Supplements</i> , <b>2007</b> , 9, C3-C74	1.5	25
597	Effect of on-admission antiplatelet treatment on patients with cerebral hemorrhage. <b>2007</b> , 24, 215-8		40
596	A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). <b>2007</b> , 36, 151-6		215
595	The increasing incidence of anticoagulant-associated intracerebral hemorrhage. <b>2007</b> , 68, 116-21		375
594	Incidence of major bleeding complication of warfarin therapy in Japanese patients with atrial fibrillation. <b>2007</b> , 71, 761-5		80
593	Anticoagulation with warfarin in vitreoretinal surgery. <b>2007</b> , 27, 290-5		33
592	Trend in mortality after stroke with atrial fibrillation. <b>2007</b> , 120, 47-53		75
591	Guías de práctica clínica sobre diabetes, prediabetes y enfermedades cardiovasculares: versión resumida. <b>2007</b> , 60, 525.e1-525.e64		7
590	The impact of warfarin use on clinical outcomes in atrial fibrillation: a population-based study. <b>2007</b> , 23, 457-61		24
589	Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. <b>2007</b> , 146, 857-67		3032

588	Transient atrial fibrillation complicating acute inferior myocardial infarction: implications for future risk of ischemic stroke. <b>2007</b> , 132, 44-9	82
587	Clinical predictors of left atrial thrombus and spontaneous echocardiographic contrast in patients with atrial fibrillation. <b>2007</b> , 20, 1181-5	46
586	Quelles prcautions chez un patient en arythmie complte par fibrillation auriculaire avant une anesthsie ?. <b>2007</b> , 11, 290-300	
585	Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. <b>2007</b> , 50, 2156-61	354
584	Atrial Fibrillation. <b>2007</b> , 489-501	
583	GUIDELINES ON DIABETES, PRE-DIABETES, AND CARDIOVASCULAR DISEASES. <b>2007</b> , 3, 88-111	2
582	Atrial fibrillation ablation in Brazil: results of the registry of the Brazilian Society of Cardiac Arrhythmias. <b>2007</b> , 89, 258-62, 285-9	9
581	AMERICAN COLLEGE OF CARDIOLOGY, AMERICAN HEART ASSOCIATION AND EUROPEAN SOCIETY OF CARDIOLOGY GUIDELINES (2006) FOR THE MANAGEMENT OF PATIENTS WITH ATRIAL FIBRILLATION (ENDING). <b>2007</b> , 3, 84-111	
580	Atrial fibrillation: insights from clinical trials and novel treatment options. <b>2007</b> , 262, 593-614	17
579	Warfarin therapy initiated before is more beneficial than after transesophageal echocardiography detected left atrial thrombus. <b>2007</b> , 24, 14-9	3
578	Atrial fibrillation and stroke prevention. <b>2007</b> , 6, 981-93	174
577	Outcome parameters for trials in atrial fibrillation: executive summary. <b>2007</b> , 28, 2803-17	267
576	Misuse of antithrombotic therapy in atrial fibrillation patients: frequent, pervasive and persistent. <b>2007</b> , 23, 65-71	23
575	Akuttherapie lebensbedrohlicher tachykarder Rhythmusstrungen. <b>2007</b> , 44, 208-218	8
574	[Outcome parameters for AF trials--executive summary of an AFNET-EHRA consensus conference]. <b>2007</b> , 18, 259-68	1
573	Underuse of oral anticoagulants in patients with nonvalvular atrial fibrillation in Italy. <b>2007</b> , 2, 24-8	32
572	Anticoagulation in patients with acute ischemic stroke and atrial fibrillation--a balance of risks and benefits. <b>2008</b> , 22, 419-25	11
571	Anticoagulation in atrial fibrillation: selected controversies including optimal anticoagulation intensity, treatment of intracerebral hemorrhage. <b>2008</b> , 25, 26-32	16

570	Advancement in antithrombotics for stroke prevention in atrial fibrillation. <b>2008</b> , 22, 129-37	19
569	Application of a decision support tool for anticoagulation in patients with non-valvular atrial fibrillation. <b>2008</b> , 23, 411-7	25
568	Increasing US emergency department visit rates and subsequent hospital admissions for atrial fibrillation from 1993 to 2004. <b>2008</b> , 51, 58-65	130
567	Atrial fibrillation treatment in the elderly: are we getting closer to an answer?. <b>2008</b> , 19, 812-4	7
566	Pharmacotherapy of Atrial Fibrillation. <b>2008</b> , 3, 153-161	
565	Warfarin anticoagulation intensity in specialist-based and in computer-assisted dosing practice. <b>2008</b> , 30, 382-9	7
564	Intensity of anticoagulation in octogenarians with nonvalvular atrial fibrillation. <b>2008</b> , 56, 1967-8	2
563	Psychotropic medications and motor vehicle collisions in patients with dementia. <b>2008</b> , 56, 1968-70	12
562	Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). <b>2008</b> , 133, 257S-298S	549
561	Cardio-embolic stroke. <b>2009</b> , 93, 719-49	1
560	Management of warfarin-related intracerebral hemorrhage. <b>2008</b> , 8, 271-90	16
559	Antithrombotic drug development for atrial fibrillation: proceedings, Washington, DC, July 25-27, 2005. <b>2008</b> , 155, 829-40	14
558	Warfarin for the prevention of systemic embolism in patients with non-valvular atrial fibrillation: a meta-analysis. <b>2008</b> , 94, 1607-13	47
557	New insights into stroke in chronic kidney disease. <b>2008</b> , 15, 338-46	9
556	Anticoagulation: stroke prevention in patients with atrial fibrillation. <b>2008</b> , 92, 143-59, xi	8
555	Stroke prevention in atrial fibrillation and other major cardiac sources of embolism. <b>2008</b> , 26, 1129-60, x-xi	25
554	Reducing the risk for stroke in patients who have atrial fibrillation. <b>2008</b> , 26, 267-75, vii	13
553	Atrial fibrillation pharmacotherapy after hospital discharge between 1995 and 2004: a shift towards beta-blockers. <b>2008</b> , 10, 395-402	19

552	The predictive value of left atrial size for incident ischemic stroke and all-cause mortality in African Americans: the Atherosclerosis Risk in Communities (ARIC) Study. <b>2008</b> , 39, 2701-6	56
551	Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). <b>2008</b> , 133, 199S-233S	350
550	Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). <b>2008</b> , 133, 546S-592S	595
549	Use of anticoagulation in elderly patients with atrial fibrillation who are at risk for falls. <b>2008</b> , 42, 523-32	69
548	Clinical Guide to the Use of Antithrombotic Drugs in Coronary Artery Disease. <b>2008</b> ,	
547	Epidemiological implications of primary and secondary stroke prevention. <b>2009</b> , 92, 389-405	
546	Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). <b>2008</b> , 133, 160S-198S	1648
545	Valvular and structural heart disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). <b>2008</b> , 133, 593S-629S	199
544	Warfarin-related intracerebral hemorrhage: how to proceed. <b>2008</b> , 4, 299-310	
543	Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based. <b>2008</b> , 111, 4471-6	76
542	Should we abandon the common practice of withholding oral anticoagulation in paroxysmal atrial fibrillation?. <b>2008</b> , 29, 915-22	90
541	Etiology, pathophysiology, and treatment of atrial fibrillation: part 1. <b>2008</b> , 16, 181-8	18
540	Treatment of atrial fibrillation and atrial flutter: Part II. <b>2008</b> , 16, 230-9	10
539	Role of anticoagulation therapy after pulmonary vein antrum isolation for atrial fibrillation treatment. <b>2008</b> , 9, 51-5	17
538	. <b>2008</b> ,	4
537	Atrial Mechanical Function after Atrial Fibrillation Ablation. <b>2009</b> , 225-232	
536	Brain Embolism. <b>2009</b> , 316-374	1
535	How well does the target INR level maintain in warfarin-treated patients with non-valvular atrial fibrillation?. <b>2009</b> , 50, 83-8	13

534	SAFETY OF LONGTERM THERAPY WITH WARFARIN: POSSIBILITY OF TREATMENT RENEWING AFTER HEMORRHAGIC COMPLICATIONS. <b>2009</b> , 5, 89-94	1
533	Cardiac Disorders and Stroke in Children and Young Adults. <b>2009</b> , 135-159	
532	Incidence of thromboembolic stroke and of major bleeding in patients with atrial fibrillation and chronic kidney disease treated with and without warfarin. <b>2009</b> , 2, 33-7	26
531	Reducing stroke rates in patients with atrial fibrillation: how low can we go?. <b>2009</b> , 120, 1169-70	3
530	Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. <b>2009</b> , 20, 2223-33	327
529	Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. <b>2009</b> , 40, 1410-6	259
528	Contemporary management of atrial fibrillation: update on anticoagulation and invasive management strategies. <b>2009</b> , 84, 643-62	51
527	Improving antithrombotic management in patients with atrial fibrillation: current status and perspectives. <b>2009</b> , 35, 527-42	23
526	Use and underuse of oral anticoagulation for stroke prevention in atrial fibrillation: old and new paradigms. <b>2009</b> , 35, 554-9	21
525	Management strategies for optimal control of anticoagulation in patients with atrial fibrillation. <b>2009</b> , 35, 560-7	15
524	Anticoagulant management in patients with atrial fibrillation. <b>2009</b> , 35, 543-7	1
523	The first evaluation of a novel vitamin K antagonist, tecarfarin (ATI-5923), in patients with atrial fibrillation. <b>2009</b> , 120, 1029-35, 2 p following 1035	66
522	Left atrial appendage occlusion eliminates the need for warfarin. <b>2009</b> , 120, 1919-26; discussion 1926	37
521	Influence of structural heart disease on characteristics of atrial fibrillation recurrence in patients with dual-chamber pacemakers. <b>2009</b> , 42, 128-35	2
520	Acute and chronic management of atrial fibrillation in patients with late-stage CKD. <b>2009</b> , 53, 701-10	16
519	[Antithrombotic therapy in atrial fibrillation: when vitamin K antagonists? When aspirin? When heparin? When combinations of anticoagulant and antiplatelet drugs?]. <b>2009</b> , 20, 61-9	
518	Antikoagulation bei Vorhofflimmern [Altes und Neues. <b>2009</b> , 4, 176-183	0
517	Clinical consequences of hospital variation in use of oral anticoagulant therapy after first-time admission for atrial fibrillation. <b>2009</b> , 265, 335-44	3

516	Warfarin is not needed in low-risk patients following atrial fibrillation ablation procedures. <b>2009</b> , 20, 988-93	62
515	Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of thromboembolic events. <b>2009</b> , 20, 241-8	271
514	Vitamin K: a practical guide to the dietary management of patients on warfarin. <b>1999</b> , 57, 288-96	61
513	Atrial fibrillation and coagulation: who and when?. <b>2009</b> , 23, 241-4	3
512	An approach to therapy of supraventricular tachyarrhythmias: an algorithm versus individualized therapy. <b>1994</b> , 17, 1121-6	2
511	Treatment. <b>2009</b> , 146-217	
510	[Oral anticoagulants and atrial fibrillation]. <b>2009</b> , 30, 311-5	
509	Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. <b>2009</b> , 157, 805-10, 810.e1-2	256
508	Cerebrovascular Disease. <b>2009</b> , 133-214	1
507	Variability in the prescription of cardiovascular medications in older patients: correlates and potential explanations. <b>2009</b> , 26 Suppl 1, 41-51	7
506	Antithrombotic Therapy According to the Guidelines Issued by the Japanese Circulation Society in Patients with Nonvalvular Paroxysmal Atrial Fibrillation without Thromboembolic Risk Factors. <b>2009</b> , 25, 81-88	
505	Combination of clopidogrel and aspirin for reduction of vascular events in patients with atrial fibrillation. <b>2009</b> , 7, 749-53	1
504	Stroke prevention in atrial fibrillation: WATCHMAN versus warfarin. <b>2009</b> , 7, 727-9	11
503	Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. <b>2009</b> , 374, 534-42	1373
502	Contemporary Management of Atrial Fibrillation: Update on Anticoagulation and Invasive Management Strategies. <b>2009</b> , 84, 643-662	40
501	Milestones in the management of atrial fibrillation. <b>2009</b> , 6, S62-7	32
500	Anticoagulation: stroke prevention in patients with atrial fibrillation. <b>2009</b> , 27, 125-35, ix	5
499	The current role of anticoagulants in cardiovascular medicine. <b>2009</b> , 10, 595-604	13



498	Measuring quality of oral anticoagulation care: extending quality measurement to a new field. <b>2009</b> , 35, 146-55	41
497	New anticoagulants for atrial fibrillation. <b>2009</b> , 10, 446-53	3
496	Current therapeutic strategies and future perspectives for the prevention of arterial thromboembolism: focus on atrial fibrillation. <b>2010</b> , 16, 3455-71	11
495	Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate. <b>2010</b> , 104, 1106-15	90
494	Lower versus standard intensity oral anticoagulant therapy (OAT) in elderly warfarin-experienced patients with non-valvular atrial fibrillation. <b>2010</b> , 103, 442-9	37
493	Treatment of coagulopathy in intracranial hemorrhage. <b>2010</b> , 12, 113-28	13
492	Angiotensinogen polymorphisms and acquired atrial fibrillation in Chinese. <b>2010</b> , 43, 373-7	19
491	Liver function tests and absolute lymphocyte count at day +100 are predictive factors for extensive and severe chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplant. <b>2010</b> , 85, 290-3	1
490	Magnetic resonance evaluation of hepatic and myocardial iron deposition in transfusion-independent thalassemia intermedia compared to regularly transfused thalassemia major patients. <b>2010</b> , 85, 288-90	50
489	Is the JAK2(V617F) mutation detectable in healthy volunteers?. <b>2010</b> , 85, 287-8	28
488	Detection of hereditary hemochromatosis and biochemical iron overload in primary care: a multicenter case finding study in Spain. <b>2010</b> , 85, 294-6	4
487	Development of Libman-Sacks endocarditis in FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome despite continuous imatinib mesylate therapy and continuous complete remission. <b>2010</b> , 85, 296-9	
486	Cardiac tamponade or hemopericardium are not associated with bleeding risk factors in consecutive patients hospitalized with noniatrogenic, pericardial effusions. <b>2010</b> , 85, 300-1	1
485	ASH 2009 meeting report—Top 10 clinically oriented abstracts in acute leukemia. <b>2010</b> , 85, 277-280	0
484	ASH 2009 meeting report—Top 10 clinically oriented abstracts in lymphoma. <b>2010</b> , 85, 280-283	
483	ASH 2009 meeting report—Top 10 clinically oriented abstracts in chronic myeloid leukemia. <b>2010</b> , 85, 283-286	0
482	Optimal loading dose for the initiation of warfarin: a systematic review. <b>2010</b> , 10, 18	20
481	Intracranial and fatal bleeding according to indication for long-term oral anticoagulant therapy. <b>2010</b> , 8, 2201-7	32

480	New-onset atrial fibrillation and warfarin initiation: high risk periods and implications for new antithrombotic drugs. <b>2010</b> , 104, 1099-105	91
479	[Warfarin and phenprocoumon: experience of an outpatient anticoagulation clinic]. <b>2010</b> , 94, 41-5	13
478	Prevalence of transthoracic echocardiographic abnormalities in patients with ischemic stroke, intracerebral hemorrhage, and subarachnoid hemorrhage. <b>2010</b> , 6, 40-2	16
477	Cardiac Arrhythmias. <b>2010</b> , 327-337	
476	Current issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolism. <b>2010</b> , 4, 51-60	83
475	Relationship between CHADS2 score and ischemic stroke during rhythm control therapy for paroxysmal atrial fibrillation. <b>2010</b> , 51, 24-9	12
474	Impact of dronedarone in atrial fibrillation and flutter on stroke reduction. <b>2010</b> , 5, 63-9	11
473	Long-term oral anticoagulation therapy and the risk of hip fracture in patients with previous hemispheric infarction and nonrheumatic atrial fibrillation. <b>2010</b> , 29, 73-8	18
472	Handbook of Oral Anticoagulation. <b>2010</b> ,	
471	Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. <b>2010</b> , 170, 1433-41	580
470	Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W. <b>2010</b> , 31, 2133-40	26
469	Self-monitoring and self-management of oral anticoagulation. <b>2010</b> , CD003839	73
468	Recent advances in oral anticoagulation for atrial fibrillation. <b>2010</b> , 4, 395-407	5
467	Antikoagulation bei Vorhofflimmern. <b>2010</b> , 6, 257-272	
466	Stroke prevention in atrial fibrillation patients. <b>2010</b> , 11, 2331-50	4
465	Principles of Anticoagulation and New Therapeutic Agents in Atrial Fibrillation. <b>2010</b> , 2, 479-492	0
464	Optimal loading dose of warfarin for the initiation of oral anticoagulation. <b>2010</b> ,	
463	Age as a risk factor for stroke in atrial fibrillation patients: implications for thromboprophylaxis. <b>2010</b> , 56, 827-37	168

462	Antithrombotic treatment for the primary prevention of stroke in patients with non valvular atrial fibrillation: a reappraisal of the evidence and network meta analysis. <b>2010</b> , 142, 218-23	9
461	A simple electrocardiogram marker for risk stratification of ischemic stroke in low-resources settings. <b>2010</b> , 19, 388-92	11
460	The effect and safety of the antithrombotic therapies in patients with atrial fibrillation and CHADS score 1. <b>2010</b> , 21, 501-7	38
459	Genetics and Genomics of Arrhythmias. <b>2010</b> , 350-373	
458	Predictors of warfarin use in atrial fibrillation patients in the inpatient setting. <b>2010</b> , 10, 37-48	38
457	Hemorrhagic and thrombotic events associated with generic substitution of warfarin in patients with atrial fibrillation: a retrospective analysis. <b>2011</b> , 45, 701-12	20
456	2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and The Heart Rhythm Society. <b>2011</b> , 57, e101-98	645
455	2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <b>2011</b> , 57, 223-42	224
454	Antithrombotic therapy in nonvalvular atrial fibrillation: a narrative review. <b>2011</b> , 30, 905-24	4
453	2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <b>2011</b> , 8, 157-76	100
452	Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. <b>2011</b> , 27, 74-90	227
451	A review of the safety of anticoagulants in older people using the medicines management pathway: weighing the benefits against the risks. <b>2011</b> , 2, 45-58	25
450	Prognostic impact of atrial fibrillation progression in a community study: AFBAR Study (Atrial Fibrillation in the Barbanza Area Study). <b>2011</b> , 153, 68-73	22
449	[Neurology and cardiology: points of contact]. <b>2011</b> , 64, 319-27	9
448	Neurology and Cardiology: Points of Contact. <b>2011</b> , 64, 319-327	
447	Antithrombotic therapy in nonvalvular atrial fibrillation: A narrative review. <b>2011</b> , 30, 905-924	3
446	Endothelial dysfunction in paroxysmal atrial fibrillation as a prothrombotic state. Comparison with permanent/persistent atrial fibrillation. <b>2011</b> , 18, 298-304	20
445	Outcome variables in multivariable analysis. 25-73	

444	Cost efficiency of anticoagulation with warfarin to prevent stroke in medicare beneficiaries with nonvalvular atrial fibrillation. <b>2011</b> , 42, 112-8	69
443	Mitral annular calcification predicts cardiovascular morbidity and mortality in middle-aged patients with atrial fibrillation: the Belgrade Atrial Fibrillation Study. <b>2011</b> , 140, 902-910	34
442	Atrial fibrillation in chronic hemodialysis patients: prevalence, types, predictors, and treatment practices in Greece. <b>2011</b> , 35, 916-22	16
441	The Society of Thoracic Surgeons practice guideline on the prophylaxis and management of atrial fibrillation associated with general thoracic surgery: executive summary. <b>2011</b> , 92, 1144-52	84
440	Dabigatran in atrial fibrillation: pharmacology and clinical trials. <b>2011</b> , 32, 173-80	6
439	Einsatz von neuen Antikoagulanzen bei kardiovaskulären Erkrankungen. <b>2011</b> , 5, 129-144	
438	Prevention of cardioembolic stroke. <b>2011</b> , 8, 488-502	21
437	Stroke prevention treatment of patients with atrial fibrillation: old and new. <b>2011</b> , 11, 15-27	
436	Usability of an atrial fibrillation anticoagulation decision-support tool. <b>2011</b> , 2, 100-6	8
435	The business case for quality improvement: oral anticoagulation for atrial fibrillation. <b>2011</b> , 4, 416-24	38
434	Pharmacological management of atrial fibrillation: one, none, one hundred thousand. <b>2011</b> , 2011, 874802	1
433	2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <b>2011</b> , 123, 104-23	298
432	Achieving target international normalization ratio in haemodialysis patients with atrial fibrillation: is it feasible?. <b>2011</b> , 4, 279	
431	The role of apixaban for venous and arterial thromboembolic disease. <b>2011</b> , 45, 1262-83	15
430	2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. <b>2011</b> , 123, e269-367	643
429	Antiplatelet therapy in stroke prevention. <b>2012</b> , 47, 141-54	4
428	Two centuries of neurology and psychiatry in the Journal. <i>New England Journal of Medicine</i> , <b>2012</b> , 367, 58-65	59.2 5
427	Why is warfarin underused for stroke prevention in atrial fibrillation? A detailed review of electronic medical records. <b>2012</b> , 28, 1407-14	21

426	Perceived or actual barriers to warfarin use in atrial fibrillation based on electronic medical records. <b>2012</b> , 19, 330-7	22
425	More light at the end of the tunnel - apixaban in atrial fibrillation. <b>2012</b> , 21, 1235-9	13
424	New oral anticoagulants for stroke prevention in atrial fibrillation: impact of gender, heart failure, diabetes mellitus and paroxysmal atrial fibrillation. <b>2012</b> , 10, 1471-80	37
423	Optimal loading dose of warfarin for the initiation of oral anticoagulation. <b>2012</b> , 12, CD008685	19
422	Stroke Prevention in Atrial Fibrillation: Where are We Now?. <b>2012</b> , 6, 65-78	8
421	Preventing stroke in atrial fibrillation patients - clinical utility of oral anticoagulants. <b>2012</b> , 3, 1-13	
420	Novel anticoagulants in atrial fibrillation stroke prevention. <b>2012</b> , 3, 123-36	15
419	Stroke prevention in atrial fibrillation: concepts and controversies. <b>2012</b> , 8, 290-301	8
418	Atrial fibrillation in acute ST-elevation myocardial infarction: clinical and prognostic features. <b>2012</b> , 8, 281-9	17
417	Antiplatelet and anticoagulation strategies in the prevention and treatment of ischemic stroke. <b>2012</b> , 18, 5261-72	5
416	Stroke prevention in atrial fibrillation. <b>2012</b> , 13, 73-85	10
415	Stroke risk assessment in atrial fibrillation. <b>2012</b> , 10-29	1
414	Prevention of embolic strokes: the role of the American College of Chest Physicians. <b>2012</b> , 141, 294-299	8
413	New oral anticoagulants for stroke prevention in atrial fibrillation. <b>2012</b> , 22-33	
412	Prophylaxis and management of atrial fibrillation after general thoracic surgery. <b>2012</b> , 22, 13-23, v	16
411	Aspirin in stroke prevention in nonvalvular atrial fibrillation and stable vascular disease: an era of new anticoagulants. <b>2012</b> , 10, 433-9	6
410	Detection of asymptomatic paroxysmal atrial fibrillation with the trans-telephonic electrocardiograph system. <b>2012</b> , 18, 193-7	1
409	Warfarin use in nursing home residents: results from the 2004 national nursing home survey. <b>2012</b> , 10, 25-36.e2	18

408	Relation of gender-specific risk of ischemic stroke in patients with atrial fibrillation to differences in warfarin anticoagulation control (from AFFIRM). <b>2012</b> , 110, 1799-802	71
407	Assessment of advantages and disadvantages of agents used for therapeutic anticoagulation. <b>2012</b> , 58, 462-8	
406	Atrial Fibrillation Management in Elderly. <b>2012</b> , 6, 431-442	1
405	Left atrial strain is reduced in patients with atrial fibrillation, stroke or TIA, and low risk CHADS(2) scores. <b>2012</b> , 25, 1327-32	65
404	Anticoagulation versus placebo for heart failure in sinus rhythm. <b>2012</b> , CD003336	10
403	Benchmark for time in therapeutic range in venous thromboembolism: a systematic review and meta-analysis. <b>2012</b> , 7, e42269	64
402	Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis. <b>2012</b> , 7, e44064	113
401	Patterns of warfarin use and subsequent outcomes in atrial fibrillation in primary care practices. <b>2012</b> , 8, 587-98	16
400	Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <b>2012</b> , 141, e44S-e88S	1112
399	Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <b>2012</b> , 141, e531S-e575S	763
398	Apixaban: a new option for stroke prevention in atrial fibrillation?. <b>2012</b> , 13, 8-13	
397	New anticoagulants for the prevention of stroke in atrial fibrillation. <b>2012</b> , 26, 47-53	6
396	Effect of pharmacological therapies for stroke prevention on major gastrointestinal bleeding in patients with atrial fibrillation. <b>2012</b> , 66, 53-63	49
395	Anticoagulation management in clinical practice: preventing stroke in patients with atrial fibrillation. <b>2012</b> , 41, 146-56	6
394	Effect of warfarin on outcomes in septuagenarian patients with atrial fibrillation. <b>2012</b> , 109, 370-7	13
393	High-risk antimicrobial prescriptions among ambulatory patients on warfarin. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2012</b> , 37, 157-60	2.2 12
392	Proportion of patients with implanted permanent pacemakers with atrial fibrillation receiving appropriate medical prophylaxis in North Wales. <b>2012</b> , 35, 935-42	1
391	Oral anticoagulant therapy in Italian patients 80 yr of age or older with atrial fibrillation: a pilot study of low vs. standard PT/INR targets. <i>European Journal of Haematology</i> , <b>2012</b> , 89, 81-6	3.8 5

390	Novel antithrombotic agents for atrial fibrillation. <b>2012</b> , 134, 345-54	3
389	Relationship between CHA(2)DS(2)-VASc scores and ischemic stroke/cardiovascular events in Japanese patients with paroxysmal atrial fibrillation not receiving anticoagulant therapy. <b>2012</b> , 59, 321-8	19
388	Antithrombotic therapy for stroke prevention in atrial fibrillation and mechanical heart valves. <b>2012</b> , 87 Suppl 1, S100-7	4
387	Promise of factor Xa inhibition in atrial fibrillation. <b>2012</b> , 14, 70-8	2
386	Incidence and management of ischemic stroke and intracerebral hemorrhage in patients on dabigatran etexilate treatment. <b>2012</b> , 16, 203-9	30
385	Utilisation of antithrombotic therapy for stroke prevention in atrial fibrillation in a Sydney hospital: then and now. <b>2012</b> , 34, 88-97	15
384	Estimated medical cost reductions associated with apixaban in real-world patients with non-valvular atrial fibrillation. <b>2013</b> , 16, 1193-202	11
383	Bleeding risk in atrial fibrillation patients taking vitamin K antagonists: systematic review and meta-analysis. <b>2013</b> , 94, 367-75	17
382	Mechanical closure of the left atrial appendage: is it time to be more aggressive?. <b>2013</b> , 146, 1018-1027.e2	22
381	Gender and the risk of stroke in atrial fibrillation: impact of old and new anticoagulation regimens. <b>2013</b> , 8, 38-45	1
380	Anti-coagulation, anti-platelets or no therapy in haemodialysis patients with atrial fibrillation: A decision analysis. <b>2013</b> , 18, 783-9	2
379	Missed opportunities for appropriate anticoagulation among emergency department patients with uncomplicated atrial fibrillation or flutter. <b>2013</b> , 62, 557-565.e2	31
378	Handbook of Oral Anticoagulation. <b>2013</b> ,	1
377	Bleeding complications associated with warfarin treatment in ischemic stroke patients with atrial fibrillation: a population-based cohort study. <b>2013</b> , 22, 561-9	17
376	[Development of neurology in Germany after 1960]. <b>2013</b> , 84, 1512-22	2
375	New avenues for anticoagulation in atrial fibrillation. <b>2013</b> , 93, 68-77	20
374	Impact of atrial fibrillation on outcomes in heart failure. <b>2013</b> , 9, 437-49, viii	0
373	Fibrillation atriale non valvulaire : traitement antithrombotique conventionnel (antivitamines K et antiagrégants plaquettaires). <b>2013</b> , 5, 132-140	

372	The type of atrial fibrillation is associated with long-term outcome in patients with acute ischemic stroke. <b>2013</b> , 167, 1519-23	15
371	Evaluaci3n de riesgo tromboemb3lico y hemorr3gico de los pacientes con fibrilaci3n auricular. <b>2013</b> , 13, 9-13	0
370	Antithrombotic therapy in atrial fibrillation: aspirin is rarely the right choice. <b>2013</b> , 89, 346-51	7
369	Risk versus benefit of non-vitamin K dependent anticoagulants compared to warfarin for the management of atrial fibrillation in the elderly. <b>2013</b> , 30, 513-25	15
368	Application of randomized clinical trial data to actual practice: apixaban therapy for reduction of stroke risk in non-valvular atrial fibrillation patients. <b>2013</b> , 29, 1253-61	7
367	Aortic sclerosis and mitral annulus calcification: a window to vascular atherosclerosis?. <b>2013</b> , 11, 863-77	13
366	Stroke Stop Study: Editorial comment. <b>2013</b> , 15, 5-6	4
365	Alternatives to warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a look back at the state of the field in 2012. <b>2013</b> , 125, 146-57	
364	Adherence and variability in warfarin dose requirements: assessment in a prospective cohort. <b>2013</b> , 14, 151-63	12
363	Plasminogen activators and ischemic stroke: conditions for acute delivery. <b>2013</b> , 39, 406-25	5
362	Hemostasis and alterations of the central nervous system. <b>2013</b> , 39, 856-75	23
361	Stroke Pharmacogenetics. <b>2013</b> , 223-297	
360	Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF. <b>2013</b> , 6, 740-7	82
359	Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin. <b>2013</b> , 6, 567-74	117
358	Association between panic disorder and risk of atrial fibrillation:a nationwide study. <b>2013</b> , 75, 30-5	21
357	Rates of hemorrhage during warfarin therapy for atrial fibrillation. <i>Cmaj</i> , <b>2013</b> , 185, E121-7	3-5 133
356	Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study. <b>2013</b> , 128, 2192-201	206
355	Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa). <b>2013</b> , 34, 1498-505	97



354	Atrial Fibrillation. <b>2013</b> , 372-382	1
353	Target international normalized ratio values for preventing thromboembolic and hemorrhagic events in Japanese patients with non-valvular atrial fibrillation: results of the J-RHYTHM Registry. <b>2013</b> , 77, 2264-70	93
352	Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. <b>2013</b> , 110, 1087-107	278
351	Should the newer oral anticoagulants be withheld from patients with valvular AF?. <b>2013</b> , 144, 369-370	1
350	Demonstration of anticoagulation patient self-testing feasibility at an Indian Health Service facility: A case series analysis. <b>2013</b> , 11, 30-7	1
349	ANTICOAGULANT THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: DRUG CHOICE AND DOSAGE ADJUSTMENT. <b>2013</b> , 9, 292-300	
348	Effectiveness of Pharmacy Run Anticoagulation Clinics Compared to Large Clinical Trials of New Oral Anticoagulants. <b>2014</b> , 1,	
347	THE ASSESSMENT OF COMPLIANCE TO THE USE OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION ACCORDING TO THE PROFILE REGISTER. <b>2014</b> , 10, 625-630	6
346	Comparison between CHADS2 and CHA2DS2-VASc score for risk stratification of ischemic stroke in Japanese patients with non-valvular paroxysmal atrial fibrillation not receiving anticoagulant therapy. <b>2014</b> , 55, 119-25	18
345	Benefits and risks of anticoagulation resumption following traumatic brain injury. <b>2014</b> , 174, 1244-51	40
344	Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48. <b>2014</b> , 35, 1457-65	130
343	Cryptogenic stroke and diabetes: a probable link between silent atrial fibrillation episodes and cerebrovascular disease. <b>2014</b> , 12, 323-9	4
342	Seven days of non-invasive cardiac monitoring early postischaemic stroke or TIA increases atrial fibrillation detection rate compared with current guideline-based practice. <b>2014</b> , 19, 152	1
341	Incidence, mortality, and risk factors for oral anticoagulant-associated intracranial hemorrhage in patients with atrial fibrillation. <b>2014</b> , 23, 2479-2488	18
340	Atrial fibrillation, stroke, and anticoagulation in Medicare beneficiaries: trends by age, sex, and race, 1992-2010. <b>2014</b> , 3, e000756	47
339	Novel anticoagulants eliminate the need for left atrial appendage exclusion devices. <b>2014</b> , 130, 1505-14	6
338	Letter by Bertolletti et al regarding article, "Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA)". <b>2014</b> , 130, e108	5
337	Patients' preferences in anticoagulant therapy: discrete choice experiment. <b>2014</b> , 7, 912-9	22

336	Safe use of antithrombotics for stroke prevention in atrial fibrillation: consideration of risk assessment tools to support decision-making. <b>2014</b> , 5, 21-37	11
335	Stroke Risk in Patients with Implanted Cardiac Devices. <b>2014</b> , 6, 133-9	
334	Anticoagulation versus placebo for heart failure in sinus rhythm. <b>2014</b> , CD003336	16
333	Current and new oral antithrombotics in non-valvular atrial fibrillation: a network meta-analysis of 79 808 patients. <b>2014</b> , 100, 396-405	51
332	Serious bleeding events due to warfarin and antibiotic co-prescription in a cohort of veterans. <b>2014</b> , 127, 657-663.e2	41
331	Atrial Fibrillation and Stroke: A Neurologic Perspective. <b>2014</b> , 6, 31-41	1
330	Initiation of warfarin in patients with atrial fibrillation: early effects on ischaemic strokes. <b>2014</b> , 35, 1881-7	77
329	Atrial Fibrillation Therapy. <b>2014</b> ,	2
328	Antithrombotic therapy after acute ischemic stroke in patients with atrial fibrillation. <b>2014</b> , 45, 3637-42	15
327	Anticoagulation strategies for the management of postoperative atrial fibrillation. <b>2014</b> , 34, 537-61	28
326	Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient population. <b>2014</b> , 17, 771-81	12
325	Stroke prevention in atrial fibrillation: established oral anticoagulants versus novel anticoagulants-translating clinical trial data into practice. <b>2014</b> , 40, 261-8	2
324	Left atrial appendage exclusion for prevention of stroke in atrial fibrillation: review of minimally invasive approaches. <b>2014</b> , 16, 448	8
323	Atrial fibrillation in patients with cryptogenic stroke. <i>New England Journal of Medicine</i> , <b>2014</b> , 370, 2467-75.2	796
322	The association of asthma and atrial fibrillation--a nationwide population-based nested case-control study. <b>2014</b> , 176, 464-9	30
321	Significant underuse of warfarin in patients with nonvalvular atrial fibrillation: results from the China national stroke registry. <b>2014</b> , 23, 1157-63	51
320	Safety of acupuncture treatments for patients taking warfarin or antiplatelet medications: Retrospective chart review study. <b>2014</b> , 6, 492-496	9
319	Latest advances in transseptal structural heart interventions-Percutaneous Mitral Valve Repair and Left Atrial Appendage Occlusion. <b>2014</b> , 78, 1782-90	10

318	The impact of smoking on thromboembolism and mortality in patients with incident atrial fibrillation: insights from the Danish Diet, Cancer, and Health study. <b>2014</b> , 145, 559-66	40
317	Adherence to oral anticoagulants in patients with atrial fibrillation-a population-based retrospective cohort study linking health information systems in the Valencia region, Spain: a study protocol. <b>2015</b> , 5, e007613	11
316	Discontinuation/Interruption of Warfarin Therapy in Patients with Nonvalvular Atrial Fibrillation. <b>2015</b> , 21, 596-606	20
315	A unified framework for classification of methods for benefit-risk assessment. <b>2015</b> , 18, 250-9	15
314	Effectiveness and Safety of Warfarin in Dialysis Patients With Atrial Fibrillation: A Meta-Analysis of Observational Studies. <b>2015</b> , 94, e2233	22
313	Real world effectiveness of warfarin among ischemic stroke patients with atrial fibrillation: observational analysis from Patient-Centered Research into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) study. <b>2015</b> , 351, h3786	37
312	Comparison of Benefit-Risk Assessment Methods for Prospective Monitoring of Newly Marketed Drugs: A Simulation Study. <b>2015</b> , 18, 1057-62	3
311	A novel approach indirectly comparing benefit-risk balance across anti-thrombotic therapies in patients with atrial fibrillation. <b>2015</b> , 1, 15-28	11
310	Cardiogenic embolism in the cat. <b>2015</b> , 17 Suppl 1, S202-14	8
309	Caseous calcification of the mitral annulus associated with stroke: report of two cases. <b>2015</b> , 171, 157-60	1
308	Device-detected atrial fibrillation: what to do with asymptomatic patients?. <b>2015</b> , 65, 281-94	43
307	Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. <b>2015</b> , 36, 281-7a	196
306	Effectiveness and safety of therapy with vitamin K antagonists in Italian patients aged 80 years or older: a multicentre retrospective study comparing the Zeus algorithm with the PARMA algorithm or manual therapy. <b>2015</b> , 32, 235-41	
305	Poor adherence to anticoagulation guidelines in patients with non-valvular atrial fibrillation treated in a tertiary cardiology unit. <b>2015</b> , 7, 18-22	6
304	Management of anticoagulation in patients with acute gastrointestinal bleeding. <b>2015</b> , 47, 621-7	43
303	Editorial comment on 'A novel approach indirectly comparing benefit: risk across oral antithrombotic therapies in patients with atrial fibrillation'. Are the evidences of current dose-adjusted anticoagulation with warfarin stroke prevention for patients with atrial fibrillation sufficient enough to compare with newly developed non-vitamin K oral anticoagulants?. <b>2015</b> , 1, 83-5	0
302	Heparin bridging in warfarin anticoagulation therapy initiation could increase bleeding in non-valvular atrial fibrillation patients: a multicenter propensity-matched analysis. <b>2015</b> , 13, 182-90	20
301	Pharmacogenetics of Coumarin Anticoagulant Therapy. <b>2015</b> , 307-328	2

300	Time to Cost-Effectiveness Following Stroke Reduction Strategies in AF: Warfarin Versus NOACs Versus LAA Closure. <b>2015</b> , 66, 2728-2739			64
299	Effect of impaired renal function on the maintenance dose of warfarin in Japanese patients. <b>2015</b> , 65, 178-84			10
298	Bleeding risk, physical functioning and non-use of anticoagulation among patients with stroke and atrial fibrillation. <b>2015</b> , 108, 189-96			1
297	Effect of obstructive sleep apnea on frequency of stroke in patients with atrial fibrillation. <b>2015</b> , 115, 461-5			64
296	Management of Atrial Fibrillation. <i>Journal of Intensive Care Medicine</i> , <b>2015</b> , 30, 484-98	3-3		5
295	Comprehensive Management of High Risk Cardiovascular Patients. <b>2016</b> ,			1
294	Treatment and Prevention of Feline Arterial Thromboembolism. <b>2016</b> , 369-378			1
293	Primary prevention of cardiovascular disease. <b>2016</b> , 19, 90-94			
292	Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trial. <b>2016</b> , 179, 59-68			29
291	Do left atrial appendage morphology and function help predict thromboembolic risk in atrial fibrillation?. <b>2016</b> , 17, 169-76			6
290	Influence of APOE Gene Polymorphism on Interindividual and Interethnic Warfarin Dosage Requirement: A Systematic Review and Meta-Analysis. <b>2016</b> , 34, 297-307			5
289	Anticoagulation Therapy and NOACs in Heart Failure. <i>Handbook of Experimental Pharmacology</i> , <b>2017</b> , 243, 515-535	3-2		4
288	Costos asociados a la fibrilaci3n auricular. <b>2016</b> , 23, 192-197			1
287	Tratamiento farmacol3gico de la fibrilaci3n auricular. Antiarr3micos y anticoagulantes orales. <b>2016</b> , 16, 33-39			
286	Comparative Effectiveness of Interventions for Stroke Prevention in Atrial Fibrillation: A Network Meta-Analysis. <b>2016</b> , 5,			43
285	Adequate time in therapeutic INR range using triple antithrombotic therapy is not associated with long-term cardiovascular events and major bleeding complications after drug-eluting stent implantation. <b>2016</b> , 68, 517-522			6
284	The C of CHADS: Historical perspective and clinical applications for anticoagulation in patients with non valvular atrial fibrillation and congestive heart failure. <b>2016</b> , 224, 431-436			3
283	Introduction and perspective. 1-18			

282	Brain embolism. 312-363	0
281	Risk of Direct Oral Anticoagulant Bioaccumulation in Patients with Pulmonary Hypertension. <b>2016</b> , 91, 307-15	15
280	How Well Do Stroke Risk Scores Predict Hemorrhage in Patients With Atrial Fibrillation?. <b>2016</b> , 118, 697-9	9
279	WITHDRAWN: Antiplatelet agents versus control or anticoagulation for heart failure in sinus rhythm. <b>2016</b> , CD003333	
278	Cardiac Diseases. <b>2016</b> , 563-575.e5	
277	Video-assisted thoracoscopic surgery atrial clipping for atrial fibrillation. <b>2016</b> , 24, 372-4	
276	Secondary Prevention After Cardioembolic Stroke. <b>2016</b> , 111-135	
275	The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis. <b>2016</b> , 37, 1591-602	190
274	Atrial fibrillation and risk of stroke: a nationwide cohort study. <b>2016</b> , 18, 1689-1697	33
273	Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation. <b>2016</b> , 18, 973-8	16
272	Absence of left atrial stunning after cardioversion of recent-onset atrial fibrillation in patients at low-stroke risk. <b>2017</b> , 24, 217-223	2
271	Influenza vaccination reduces hemorrhagic stroke risk in patients with atrial fibrillation: A population-based cohort study. <b>2017</b> , 232, 315-323	15
270	Thromboembolic risk and effect of oral anticoagulation according to atrial fibrillation patterns: A systematic review and meta-analysis. <b>2017</b> , 40, 641-647	10
269	The Efficacy and Safety of 3 Types of Interventions for Stroke Prevention in Patients With Cardiovascular and Cerebrovascular Diseases: A Network Meta-analysis. <b>2017</b> , 39, 1291-1312.e8	1
268	2014 Chinese guidelines for secondary prevention of ischemic stroke and transient ischemic attack. <b>2017</b> , 12, 302-320	52
267	Oral Anticoagulants to Prevent Stroke in Nonvalvular Atrial Fibrillation in Patients With CKD Stage 5D: An NKF-KDOQI Controversies Report. <b>2017</b> , 70, 859-868	21
266	Left Atrial Size and Long-Term Risk of Recurrent Stroke After Acute Ischemic Stroke in Patients With Nonvalvular Atrial Fibrillation. <b>2017</b> , 6,	28
265	Device Therapy for Rate Control: Pacing, Resynchronisation and AV Node Ablation. <b>2017</b> , 26, 934-940	11

264	Risk analysis of new oral anticoagulants for gastrointestinal bleeding and intracranial hemorrhage in atrial fibrillation patients: a systematic review and network meta-analysis. <b>2017</b> , 18, 567-576	12
263	Interventional and surgical occlusion of the left atrial appendage. <b>2017</b> , 14, 727-743	24
262	Patients With Atrial Fibrillation: Switching Emphasis From Stroke Prevention to Stroke and Hemorrhage Prevention. <b>2017</b> , 3, 1377-1379	
261	Bleeding events associated with a low dose (110 mg) versus a high dose (150 mg) of dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis. <b>2017</b> , 17, 83	3
260	Atrial fibrillation in women: treatment. <b>2017</b> , 14, 113-124	43
259	Antiplatelet and Anticoagulant Therapies for Prevention of Ischemic Stroke. <b>2017</b> , 23, 301-318	32
258	Rationale and design of ASSAF-K (A study of the safety and efficacy of anticoagulant therapy in the treatment of atrial fibrillation in Kanagawa). <b>2017</b> , 33, 111-116	0
257	Oral Anticoagulants Initiation in Patients with Atrial Fibrillation: Real-World Data from a Population-Based Cohort. <b>2017</b> , 8, 63	26
256	A Multilevel Analysis of Real-World Variations in Oral Anticoagulation Initiation for Atrial Fibrillation in Valencia, a European Region. <b>2017</b> , 8, 576	2
255	Patient Characteristics and Clinical Outcomes with Low-Dose Dabigatran. <b>2017</b> , 4, 42	1
254	Oral anticoagulant persistence in patients with non-valvular atrial fibrillation: A cohort study using primary care data in Germany. <b>2017</b> , 12, e0185642	22
253	Shared decision making for stroke prevention in atrial fibrillation: study protocol for a randomized controlled trial. <b>2017</b> , 18, 443	15
252	Clinical Significance of Hematuria in Atrial Fibrillation With Oral Anticoagulation Therapy. <b>2017</b> , 81, 158-164	20
251	Is anticoagulating haemodialysis patients with non-valvular atrial fibrillation too risky?. <b>2018</b> , 181, 725-736	4
250	Role of cardiac electronic implantable device in the stratification and management of embolic risk of silent atrial fibrillation: are all atrial fibrillations created equal?. <b>2018</b> , 16, 175-181	6
249	Use of non-vitamin K oral anticoagulants in people with atrial fibrillation and diabetes mellitus. <b>2018</b> , 35, 548-556	13
248	Initiation and continuation of oral anticoagulant prescriptions for stroke prevention in non-valvular atrial fibrillation: A cohort study in primary care in France. <b>2018</b> , 111, 370-379	8
247	Clinical Trials for Atrial Fibrillation—What Do We Know?. <b>2018</b> , 630-642	

246	Comparison of Aspirin and Naoxintong Capsule () with Adjusted-Dose Warfarin in Elderly Patients with High-Risk of Non-Valvular Atrial Fibrillation and Genetic Variants of Vitamin K Epoxide Reductase. <b>2018</b> , 24, 247-253	4
245	New developments in clinical ischemic stroke prevention and treatment and their imaging implications. <b>2018</b> , 38, 1533-1550	10
244	Management of patients with stroke treated with direct oral anticoagulants. <b>2018</b> , 265, 3022-3033	9
243	Prestroke and Poststroke Antithrombotic Therapy in Patients With Atrial Fibrillation: Results From a Nationwide Cohort. <b>2018</b> , 1, e180171	18
242	The Role of the Left Atrial Appendage in Stroke and Arrhythmia Provocation. <b>2018</b> , 12, 1	
241	Warfarin for prevention of thromboembolism in atrial fibrillation: comparison of patient characteristics and outcomes of the "Real-World" Michigan Anticoagulation Quality Improvement Initiative (MAQI) registry to the RE-LY, ROCKET-AF, and ARISTOTLE trials. <b>2018</b> , 46, 316-324	9
240	Screening for Atrial Fibrillation With Electrocardiography: Evidence Report and Systematic Review for the US Preventive Services Task Force. <i>JAMA - Journal of the American Medical Association</i> , <b>2018</b> , 320, 485-498	27.4 69
239	Primary Nonadherence to Oral Anticoagulants in Patients with Atrial Fibrillation: Real-World Data from a Population-Based Cohort. <b>2018</b> , 24, 440-448	19
238	Comparative thromboembolic risk in atrial fibrillation patients with and without a concurrent infection. <b>2018</b> , 204, 43-51	4
237	Cost-Effectiveness of Left Atrial Appendage Closure With the WATCHMAN Device Compared With Warfarin or Non-Vitamin K Antagonist Oral Anticoagulants for Secondary Prevention in Nonvalvular Atrial Fibrillation. <b>2018</b> , 49, 1464-1470	20
236	Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report. <b>2018</b> , 154, 1121-1201	502
235	Retrochiasmal Disorders. <b>2019</b> , 293-339	0
234	Atrial high-rate episodes: prevalence, stroke risk, implications for management, and clinical gaps in evidence. <b>2019</b> , 21, 1459-1467	24
233	Oral Anticoagulants in Patients With Atrial Fibrillation and End-Stage Renal Disease. <b>2019</b> , 24, 499-508	1
232	Atrial fibrillation in patients with end-stage renal disease on hemodialysis: Magnitude of the problem and new approach to oral anticoagulation. <b>2019</b> , 3, 578-588	13
231	Cost-Effectiveness of Left Atrial Appendage Closure for Stroke Reduction in Atrial Fibrillation: Analysis of Pooled, 5-Year, Long-Term Data. <b>2019</b> , 8, e011577	16
230	Indications and potential pitfalls of anticoagulants in pulmonary hypertension: Would DOACs become a better option than VKAs?. <b>2019</b> , 37, 100579	8
229	Cerebrovascular Disease. <b>2019</b> , 167-285	1

228	Stroke risk stratification in atrial fibrillation: a review of common risk factors. <b>2019</b> , 9, 113-120	18
227	Left atrial appendage strain rate is associated with documented thromboembolism in nonvalvular atrial fibrillation. <b>2019</b> , 131, 156-164	6
226	Anticoagulation Drug Trials for Stroke Prevention in Atrial Fibrillation. <b>2019</b> , 35-46	1
225	General Population vs. Patient Preferences in Anticoagulant Therapy: A Discrete Choice Experiment. <b>2019</b> , 12, 235-246	3
224	Warfarin therapy in atrial fibrillation: assessment of patient knowledge of risks and benefits. <b>2020</b> , 10, 179-187	1
223	Predictors of Outcomes in Patients with Atrial Fibrillation: What Can Be Used Now and What Hope Is in the Future. <b>2020</b> , 14, 1	2
222	Subclinical atrial fibrillation: when to give NAO?. <i>European Heart Journal Supplements</i> , <b>2020</b> , 22, E105-E109	0
221	Direct-Acting Oral Anticoagulants Versus Warfarin in Medicare Patients With Chronic Kidney Disease and Atrial Fibrillation. <b>2020</b> , 51, 2364-2373	14
220	Left atrial appendage occlusion for ischemic stroke prevention in patients with non-valvular atrial fibrillation: clinical expert opinion and consensus statement for the Asian-Pacific region. <b>2021</b> , 61, 269-281	1
219	Assessment of a Machine Learning Model Applied to Harmonized Electronic Health Record Data for the Prediction of Incident Atrial Fibrillation. <b>2020</b> , 3, e1919396	32
218	Comparative efficacy and safety of warfarin care bundles and novel oral anticoagulants in patients with atrial fibrillation: a systematic review and network meta-analysis. <b>2020</b> , 10, 662	9
217	Hemorrhage in Essential Thrombocythemia or Polycythemia Vera: Epidemiology, Location, Risk Factors, and Lessons Learned from the Literature. <b>2021</b> , 121, 553-564	4
216	A Study of Proton Pump Inhibitors and Other Risk Factors in Warfarin-Associated Gastrointestinal Bleeding. <b>2021</b> , 13, e12624	1
215	Towards personalized antithrombotic management with drugs and devices across the cardiovascular spectrum. <b>2021</b> ,	0
214	Machine Learning Methodologies for Prediction of Rhythm-Control Strategy in Patients Diagnosed with Atrial Fibrillation: Model Development and Comparison Study (Preprint).	
213	Comparative risk for intracranial hemorrhage related to new oral anticoagulants: A network meta-analysis. <b>2021</b> , 100, e24522	0
212	Machine Learning Methodologies for Prediction of Rhythm-Control Strategy in Patients Diagnosed With Atrial Fibrillation: Observational, Retrospective, Case-Control Study. <b>2021</b> , 9, e29225	2
211	Antithrombotic Therapy for Stroke Patients with Cardiovascular Disease. <b>2021</b> , 41, 365-387	0



210	Anticoagulation versus placebo for heart failure in sinus rhythm. <b>2021</b> , 5, CD003336	1
209	Atrial fibrillation in the elderly population: Challenges and management considerations. <b>2021</b> , 37, 912-921	2
208	Oral Anticoagulants in Atrial Fibrillation Patients With Recent Stroke Who Are Dependent on the Daily Help of Others. <b>2021</b> , 52, 3472-3481	4
207	Natural Coumarins: Exploring the Pharmacological Complexity and Underlying Molecular Mechanisms. <b>2021</b> , 2021, 6492346	9
206	Uninterrupted Direct Oral Anticoagulants Without a Change in Regimen for Catheter Ablation for Atrial Fibrillation Is an Acceptable Protocol. <b>2021</b> , 3, 481-487	
205	Prevalence, clinical profile, and stroke risk of atrial fibrillation in rural Andhra Pradesh, India (The AP-AF study) - Rationale and design. <b>2021</b> , 21, 275-280	
204	Eighty years of oral anticoagulation: Learning from history. <b>2021</b> , 141, 106918	1
203	Cardiac Diseases. <b>2022</b> , 477-487.e6	
202	Neuroophthalmologic Disease of the Retina. <b>2021</b> , 1-39	
201	Lessons From Warfarin Trials in Atrial Fibrillation: Missing the Window of Opportunity. <b>2006</b> , 312-319	2
200	Tachykarde Herzrhythmusstörungen in der Intensivmedizin. <b>2006</b> , 480-492	2
199	Arrhythmia in Patients with a Cardiomyopathy and Congestive Heart Failure. <b>1994</b> , 645-686	4
198	Coumarins. <b>1998</b> , 130-138	2
197	Cerebrovascular Disease and Stroke. <b>1997</b> , 923-938	1
196	Prevention of Recurrent Stroke. <b>1991</b> , 261-268	2
195	Diagnostik und Therapie von Tachykardien mit schmalem QRS-Komplex. <b>2001</b> , 15-27	5
194	Indications for Implanting Rate-Adaptive Cardiac Pacemakers. <b>1993</b> , 58-80	1
193	Tachykarde Rhythmusstörungen. <b>1995</b> , 35-55	0

192	Management of Atrial Fibrillation: From Palliation to Intervention. <i>Developments in Cardiovascular Medicine</i> , <b>1992</b> , 271-284		1
191	Guidelines for Competitive Athletes with Arrhythmias. <i>Developments in Cardiovascular Medicine</i> , <b>2000</b> , 119-151		3
190	Familial idiopathic atrial fibrillation with bradyarrhythmia. <b>1996</b> , 155, 7-10		5
189	The Level of Activity of the Hemostatic System, the Rate of Embolic Stroke, and Age: Is There a Correlation?. <b>1995</b> , 437-442		1
188	Stroke Syndromes. <b>2011</b> , 1177-1222		4
187	Hematologic Causes of Intracerebral Hemorrhage and Their Treatment. <b>1992</b> , 3, 637-658		29
186	Vitamin K: A Practical Guide to the Dietary Management of Patients on Warfarin. <b>1998</b> , 1, 117-125		3
185	An 8 1/2-year clinical experience with surgery for atrial fibrillation. <i>Annals of Surgery</i> , <b>1996</b> , 224, 267-73; discussion 273-5	7.8	278
184	Molecular biology and atrial fibrillation. <b>1999</b> , 14, 269-73		6
183	Modeling INR data to predict maintenance fluindione dosage. <b>1998</b> , 20, 631-9		10
182	Stroke in atrial fibrillation: a need for effective anticoagulation. <b>2004</b> , 97, 919-20		1
181	Clinical correlation between effective anticoagulants and risk of stroke: are we using evidence-based strategies?. <b>2004</b> , 97, 924-31		6
180	Development of a Prediction Model for Incident Atrial Fibrillation using Machine Learning Applied to Harmonized Electronic Health Record Data.		1
179	Radiofrequency catheter ablation of the atria reduces inducibility and duration of atrial fibrillation in dogs. <b>1995</b> , 91, 2235-44		111
178	Left atrial size and the risk of stroke and death. The Framingham Heart Study. <b>1995</b> , 92, 835-41		740
177	Management of deep vein thrombosis and pulmonary embolism. A statement for healthcare professionals. Council on Thrombosis (in consultation with the Council on Cardiovascular Radiology), American Heart Association. <b>1996</b> , 93, 2212-45		439
176	Elective stenting of extracranial carotid arteries. <b>1997</b> , 95, 303-5		26
175	High concentration of thrombomodulin in plasma is associated with hemorrhage: a prospective study in patients receiving long-term anticoagulant treatment. <b>1997</b> , 96, 2938-43		25

174	Predictors of major vascular events in patients with a transient ischemic attack or minor ischemic stroke and with nonrheumatic atrial fibrillation. European Atrial Fibrillation Trial (EAFT) Study Group. <b>1995</b> , 26, 801-6		61
173	Platelet activation is not involved in acceleration of the coagulation system in acute cardioembolic stroke with nonvalvular atrial fibrillation. <b>1995</b> , 26, 1365-8		19
172	Effect of time and cerebrovascular symptoms of the prevalence of microembolic signals in patients with cervical carotid stenosis. <b>1996</b> , 27, 687-90		36
171	Thromboembolism prophylaxis in chronic atrial fibrillation. Practice patterns in community and tertiary-care hospitals. <b>1997</b> , 28, 72-6		67
170	Warfarin use among patients with atrial fibrillation. <b>1997</b> , 28, 2382-9		156
169	Long-term oral anticoagulation reduces bone mass in patients with previous hemispheric infarction and nonrheumatic atrial fibrillation. <b>1997</b> , 28, 2390-4		41
168	Diurnal Variation in the Intensity of Anticoagulation in Atrial Fibrillation. <b>2002</b> , 33, 322-324		5
167	Brain Embolism. <b>1999</b> , 35-185		3
166	Systematic review of observational studies assessing bleeding risk in patients with atrial fibrillation not using anticoagulants. <b>2014</b> , 9, e88131		6
165	Edoxaban in the evolving scenario of non vitamin K antagonist oral anticoagulants imputed placebo analysis and multiple treatment comparisons. <b>2014</b> , 9, e100478		20
164	Exploratory Network Meta Regression Analysis of Stroke Prevention in Atrial Fibrillation Fails to Identify Any Interactions with Treatment Effect. <b>2016</b> , 11, e0161864		6
163	Influenza vaccination might reduce the risk of ischemic stroke in patients with atrial fibrillation: A population-based cohort study. <b>2017</b> , 8, 112697-112711		9
162	Tailored Anticoagulation for Thromboembolic Risk Reduction in Paroxysmal Atrial Fibrillation. <i>Journal of Innovations in Cardiac Rhythm Management</i> , <b>2018</b> , 9, 3116-3125	1.1	1
161	Antithrombotic Therapy in Patients with Recent Stroke and Atrial Fibrillation. <b>2020</b> , 26, 2715-2724		0
160	Hematoma Expansion Following Intracerebral Hemorrhage: Mechanisms Targeting the Coagulation Cascade and Platelet Activation. <b>2017</b> , 18, 1329-1344		15
159	Do antiplatelet and anticoagulant drugs modify outcome of patients treated for chronic subdural hematoma? Still a controversial issue. <b>2018</b> ,		3
158	Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis. <b>2017</b> , 21, 1-386		90
157	Evidence-based study on antithrombotic therapy in patients at risk of a stroke with paroxysmal atrial fibrillation. <b>2013</b> , 6, 413-418		2

156	Evolution of left atrial thrombus with anticoagulant therapy-follow-up by transesophageal echocardiography. <b>1995</b> , 10, 143-5		2
155	Relationship between left atrial size and stroke in patients with sinus rhythm and preserved systolic function. <b>2009</b> , 24, 24-32		14
154	Moving beyond warfarin-are we ready? A Review of the efficacy and safety of novel anticoagulant agents compared to warfarin for the management of atrial fibrillation in older adults. <b>2013</b> , 39, 8-17		3
153	Atrial Fibrillation: The New Epidemic of the Ageing World. <i>Journal of Atrial Fibrillation</i> , <b>2009</b> , 1, 154	0.8	15
152	Impact of Anticoagulation Intensity in Korean Patients with Atrial Fibrillation: Is It Different from Western Population?. <b>2020</b> , 50, 163-175		3
151	Statement on Antiplatelet Agents and Anticoagulants in Cardiology - 2019. <b>2019</b> , 113, 111-134		2
150	Prevalence of oral anticoagulation in atrial fibrillation. <b>2014</b> , 69, 615-20		8
149	Atrial fibrillation. <b>2014</b> , 28, 1-17		32
148	Fifty Years of Acute Ischemic Stroke Treatment: A Personal History. <b>2021</b> , 50, 666-680		5
147	Therapeutic Options for Established or Recurrent Atrial Fibrillation: Focus on Antithrombotic Therapy. <i>Developments in Cardiovascular Medicine</i> , <b>2000</b> , 133-139		
146	Pathogenese der Herzrhythmusstörungen. <b>2000</b> , 445-451		
145	EKG-Klassifikation: Bradykardien. <b>2000</b> , 461-467		
144	Advances in Therapy and the Management of Antithrombotic Drugs for Venous Thromboembolism. <b>2000</b> , 2000, 266-284		2
143	kardiologie und Angiologie. <b>2000</b> , 51-125		
142	Therapie: Bradykardien. <b>2000</b> , 487-497		
141	Antikoagulation Indikation, Durchführung, klinische Ergebnisse. <b>2000</b> , 79-91		
140	Therapie: Tachykardien. <b>2000</b> , 499-521		
139	Epidemiologie, klinischer Verlauf und Prognose. <b>2000</b> , 3-20		

138 Advances in Therapy and the Management of Antithrombotic Drugs for Venous Thromboembolism. **2000**, 2000, 266-284

137 Cerebrovascular Disease: Experience Within Large Multicentre Trials. **2001**, 229-249

136 Atrial Fibrillation. *Developments in Cardiovascular Medicine*, **2001**, 191-198

135 Clinical Trials in Stroke Prevention in North America. **2001**, 213-228

134 Self-management of Oral Anticoagulants by Patients with Atrial Fibrillation: How Effective and Safe Is It?. **2002**, 436-440

133 Prognosis After Stroke. **2002**,

132 Cerebrovascular Disease. **2003**, 129-149

131 Cerebrovascular Disease. **2003**, 117-198

130 Cardiac Arrhythmias. **2003**, 644-662

129 Clinical Trials in Neurology. **2004**, 399-424

128 Cardiac Diseases. **2004**, 747-759

1

127 Use of Chronic Anticoagulation in the Elderly: A Review of the Benefits and Risks. *Developments in Cardiovascular Medicine*, **2004**, 181-199

126 Cardiac Embolism. **2004**, 187-198

125 Antikogulation bei Herzerkrankungen. **2004**, 869-896

124 Cardiac Arrhythmias and the Perioperative Period. **2005**, 323-366

123 Complications of Atrial Fibrillation Ablation: How to Prevent and Manage Cerebrovascular Accidents. **2006**, 231-239

122 Prevention and Management of Thromboembolism. **2006**, 331-345

121 Antithrombotic Approaches in Cerebrovascular Disease. **2006**, 449-466

- 120 Atrial Arrhythmia. **2006**, 167-182
- 119 Anticoagulation and Antiplatelet Agents. **2006**, 501-524
- 118 Aging Changes Seen on Echocardiography. **2007**, 952-968
- 117 Cardiac disorders. **2007**, 399-428
- 116 The Role of Echocardiography in Atrial Fibrillation and Flutter. **2007**, 999-1018
- 115 Stroke. **2008**, 887-891
- 114 Neuroophthalmologic Disease of the Retina. **2008**, 3839-3859
- 113 Neurological Manifestations of Acquired Cardiac Disease, Arrhythmias, and Interventional Cardiology. **2008**, 75-95
- 112 Mitral Regurgitation, Mitral Stenosis, and Mitral Annular Calcification in the Elderly. **2008**, 445-480
- 111 Cerebrovascular Disease in the Elderly Patient. **2008**, 645-672
- 110 Supraventricular Tachyarrhythmias in the Elderly. **2008**, 577-604
- 109 Genetics and Genomics of Arrhythmias. **2009**, 729-754
- 108 Introduction and Perspective. **2009**, 3-21
- 107 Antithrombotic Therapy for Atrial Fibrillation and Cardioversion. **2010**, 389-403
- 106 Heart failure (and not only heart failure) and atrial fibrillation: an opening gap between evidence and practice. **2009**, 51, 584-589
- 105 Valvular Heart Disease. **2010**, 312-326
- 104 Retrochiasmal disorders. **2010**, 293-337
- 103 Common clinical indications for anticoagulation. **2010**, 7-25

102 [Percutaneous closure of left atrial appendage in non-valvular atrial fibrillation--international and Hungarian experiences]. **2010**, 151, 725-34

101 Pharmacologic Management of Atrial Fibrillation and Flutter. **2011**, 165-193

100 History of Supraventricular Tachycardia. **2011**, 17-38

99 Cardiac Diseases. **2011**, 814-827

1

98 Stroke. **2012**, 45-74

97 Neurologic Aspects of Kidney Disease. **2012**, 2138-2155

96 Left Atrial Appendage Closure and Stroke. **2012**, 623-634

95 Atrial Fibrillation: Current and Forthcoming Antithrombotic Therapies. 285-305

94 Atrial Fibrillation. 143-173

93 LOWERING THE RISK FOR THROMBUS AND STROKE IN ATRIAL FIBRILLATION PATIENTS: Will Dabigatran Replace Warfarin?. **2013**, 5, 1-8

92 Comparison between CHADS2 and CHA2DS2 -VASc Score for the Risk Stratification of Ischemic Stroke in Japanese Patients with Nonvalvular Paroxysmal Atrial Fibrillation. **2013**, 33, 40-48

91 ??????????????????. **2013**, 36, 345-349

90 Common Clinical Indications for Anticoagulation. **2013**, 7-31

89 Randomized controlled clinical trials versus real-life atrial fibrillation patients treated with oral anticoagulants. Do we treat the same patients?. **2020**, 27, 590-599

1

88 Proposal for Warfarin Dosage Guideline during Warfarin-Propafenone Combination Therapy. **2013**, 30, 52-63

87 Supraventricular tachycardia. 94-218

86 Novel Oral Anticoagulants for Stroke Prevention in Patients with Non-valvular Atrial Fibrillation. **2014**, 55-89

85 Present Status of Anticoagulant Prophylaxis. **1991**, 139-147

- 84 Risk and Prevention of Embolism in Atrial Fibrillation. *Developments in Cardiovascular Medicine*, **1992**, 237-257
- 83 An Organized Approach to a Disorganized Atrial Arrhythmia. **1992**, 77-86
- 82 Thromboembolism in Nonrheumatic Atrial Fibrillation: What Have We Learned?. **1992**, 83-86 2
- 81 Thrombosis. **1992**, 271-293
- 80 Atrial Fibrillation: A European Perspective. **1992**, 63-67
- 79 Disturbances of Cardiac Rhythm. *Developments in Cardiovascular Medicine*, **1993**, 163-194
- 78 Diseases of the Aorta and Arterial Tree. *Developments in Cardiovascular Medicine*, **1993**, 331-374
- 77 The Role of Ticlopidine in Prevention of Ischemic Stroke: A Benefit-Risk Assessment. **1993**, 141-155
- 76 Medical Treatment of Cardiovascular Disease. *Developments in Cardiovascular Medicine*, **1993**, 473-497
- 75 Antikoagulantientherapie im Alter. **1993**, 347-359
- 74 Gerinnungshemmende Behandlung des chronischen Vorhofflimmerns. **1994**, 89-97
- 73 Cardiac Arrhythmias. **1994**, 601-616
- 72 Anticoagulant therapy and atrial fibrillation. **1994**, 322-330
- 71 Pathogenesis and Therapy of Thrombosis in Patients with Congestive Heart Failure. **1994**, 687-700
- 70 Anticoagulant therapy and myocardial infarction. **1994**, 309-321
- 69 Elektrische Therapie von Vorhofflimmern und Vorhofflattern. **1994**, 69-86
- 68 Embolierisiko bei Vorhofflimmern Indikation zur Antikoagulation bzw. Hemmung der Thrombozytenaggregation. **1994**, 43-52
- 67 Preventing Stroke in Atrial Fibrillation: Overview of the Randomized Trials of Antithrombotic Therapy\*\*Some of the material presented in this chapter appeared in earlier versions in previous publications by the author. These include Singer et al. Preventing stroke in atrial fibrillation. *Coronary Artery Disease* 1992;2:753-760 (in particular table 3) and Singer. Overview of the randomized trials to prevent stroke in atrial fibrillation. *Ann Epidemiology* 1993;3:563-567. Permission to reprint relevant materia. **1995**, 427-436



66 Spezielle Erkrankungen mit präventivem Potential. **1995**, 67-257

65 Prefatory Comments. **1995**, 337-341

64 CURRENT CONCEPTS OF ANTICOAGULATION THERAPY. *Clinics in Chest Medicine*, **1995**, 16, 269-280 5:3 6

63 Antikoagulation und Aggregationshemmung bei Herzerkrankungen. **1996**, 1301-1339

62 Managing paroxysmal atrial tachycardias in patients with pacemakers. *Developments in Cardiovascular Medicine*, **1996**, 167-173

61 Thromboembolic Risk in Patients with Atrial Fibrillation: Can It Be Predicted on the Basis of Clinical Variables?. **1996**, 207-211

60 Is Mortality in Patients with Atrial Fibrillation Related to the Underlying Heart Disease or to the Arrhythmia?. **1996**, 203-206

59 The causes and management of atrial fibrillation. *Journal of Clinical Pharmacy and Therapeutics*, **1996**, 21, 37-43 2:2

58 Spezielle Erkrankungen mit präventivem Potential. **1997**, 193-569

57 Primär- und Sekundärprävention des Schlaganfalls. **1997**, 73-84

56 Thromboembolieschutz bei Vorhofflimmern. **1997**, 29-34

55 Clinical Aspects of Stroke and Therapeutic Strategies. **1997**, 43-66

54 Postoperative Gerinnungshemmung im Rahmen moderner koronarchirurgischer Operationsverfahren. **1997**, 61-72

53 Prophylaxe ischämischer Insulte. **1998**, 1328-1333

52 Cardiac Arrhythmias. **1998**, 664-682

51 Recognition and Management of Cardiac Arrhythmias: Part I. General Principles and Supraventricular Tachyarrhythmias. *Journal of Intensive Care Medicine*, **1998**, 13, 15-31 3:3 1

50 Spezielle Erkrankungen mit präventivem Potential. **1998**, 285-733

49 Conclusions and Questions from Large Trials of Anticoagulants in Patients with Atrial Fibrillation. *Developments in Cardiovascular Medicine*, **1998**, 43-48

48	LETTERS TO THE EDITOR. <i>Annals of Surgery</i> , <b>1998</b> , 227, 313-314	7.8	1
47	Dilated Cardiomyopathy. <i>Developments in Cardiovascular Medicine</i> , <b>1999</b> , 278-293		
46	Therapie mit oralen Antikoagulanzen. <b>1999</b> , 666-678		
45	Tachykardie Rhythmusstörungen. <b>1999</b> , 199-222		
44	Anticoagulant Therapy with Warfarin for Thrombotic Disorders. <i>Handbook of Experimental Pharmacology</i> , <b>1999</b> , 353-366	3.2	
43	Managing atrial fibrillation in elderly people. What should target international normalised ratio be?. <i>BMJ: British Medical Journal</i> , <b>1999</b> , 319, 452-3		
42	New anticoagulants in clinical practice. Effectiveness and problems. <i>Klinicheskaia Meditsina</i> , <b>2016</b> , 94, 383-387	0.2	1
41	Management of Bleeding with Non Vitamin K Oral Anticoagulants. <i>Journal of Cardiology &amp; Current Research</i> , <b>2016</b> , 7,	0.1	
40	Antiplatelet Therapy in Patients with Coronary Artery Disease. <b>2017</b> , 1361-1371		
39	Stroke Pharmacogenetics. <b>2017</b> , 327-410		
38	Catheter ablation for atrial fibrillation in prevention of stroke. <i>Intervencni A Akutni Kardiologie</i> , <b>2017</b> , 16, 71-74	0	1
37	KRAUJAVIMO RIZIKOS VEIKSNIŲ PASISKIRSTYMAS TARP PACIENTŲ KURIEMS ū VYKO SIMPTOMINIS VITAMINO K ANTAGONISTŲ PERDOZAVIMAS. <i>Health Sciences</i> , <b>2017</b> , 27, 89-93	0	
36	OBSOLETE: Clinical Trials for Atrial Fibrillation - What do we know?. <b>2018</b> ,		
35	Anticoagulation Patterns in Patients with Atrial Fibrillation Following Percutaneous Coronary Intervention in an Academic Center. <i>Journal of Innovations in Cardiac Rhythm Management</i> , <b>2019</b> , 10, 3785-3789	1.1	
34	Bleeding complications in bcr-abl-negative myeloproliferative neoplasms (MPN): A retrospective single-center study of 829 MPN patients. <i>European Journal of Haematology</i> , <b>2021</b> , 108, 154	3.8	1
33	[Clinical Practice Guideline for the Management of Antithrombotic Agents in Patients Undergoing Gastrointestinal Endoscopy]. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , <b>2020</b> , 76, 282-296	0.6	
32	Pharmacologic Management of Atrial Fibrillation and Flutter. <i>Contemporary Cardiology</i> , <b>2020</b> , 359-407	0.1	
31	Benefit and harm of anticoagulation in the prevention of thromboembolic stroke for non- valvular atrial fibrillation in haemodialysis patients - a Top End of Northern Australia study. <i>Internal Medicine Journal</i> , <b>2021</b> ,	1.6	

30	Antikoagulation Indikation, Durchführung, klinische Ergebnisse. <b>2007</b> , 141-156		
29	Spezielle therapeutische Probleme im höheren Alter. <b>2005</b> , 98-122		
28	Therapie des Vorhofflimmerns. <b>2006</b> , 115-123		
27	Monitoring Chronic Oral Anticoagulant Therapy. <b>1997</b> , 495-515		
26	Hemorrhagic Complications. <b>1997</b> , 519-544		
25	Clinical Practice Guideline for the Management of Antithrombotic Agents in Patients Undergoing Gastrointestinal Endoscopy. <i>Clinical Endoscopy</i> , <b>2020</b> , 53, 663-677	2.5	0
24	Creating a Canadian stroke system. <i>Cmaj</i> , <b>2001</b> , 164, 1853-5	3.5	5
23	Stroke Prevention in Atrial Fibrillation. <i>Journal of Atrial Fibrillation</i> , <b>2010</b> , 3, 279	0.8	1
22	Pharmacological Therapy in Stroke Prophylaxis - The New versus the Old Agents. <i>Journal of Atrial Fibrillation</i> , <b>2013</b> , 6, 825	0.8	
21	Should Atrial Fibrillation Burden Be A Feature to Guide Thromboembolism Prophylaxis?. <i>Journal of Atrial Fibrillation</i> , <b>2012</b> , 5, 530	0.8	
20	CHADS-VASc score stratifies mortality risk in patients with and without atrial fibrillation. <i>Open Heart</i> , <b>2021</b> , 8,	3	4
19	Antithrombotic Therapy in the Prevention of Stroke.. <i>Biomedicines</i> , <b>2021</b> , 9,	4.8	0
18	Screening for Atrial Fibrillation: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.. <i>JAMA - Journal of the American Medical Association</i> , <b>2022</b> , 327, 368-383	27.4	3
17	Non-vitamin K antagonist oral anticoagulants in patients with valvular heart disease.. <i>European Heart Journal Supplements</i> , <b>2022</b> , 24, A19-A31	1.5	0
16	Universal Clinician Device for improving risk prediction and management of patients with atrial fibrillation: an assumed benefit analysis. <i>European Heart Journal Digital Health</i> ,	2.3	
15	Evaluation and Interventional Management of Cardiac Dysrhythmias. <i>Surgical Clinics of North America</i> , <b>2022</b> ,	4	
14	Neuroophthalmologic Disease of the Retina. <b>2022</b> , 4449-4487		
13	NEUROLOGIC EMERGENCIES. <i>Dental Clinics of North America</i> , <b>1995</b> , 39, 567-575	3.3	2

12 Anticoagulants in Use. **2022**, 327-345

11 Perkutaner Vorhofohrverschluss nach Schlaganfall. *Nervenheilkunde*, **2022**, 41, 417-425 0.3

10 Arrhythmias. *Journal of the Royal Society of Medicine*, **1994**, 87, 87-90 2.3

9 The Impact of Landscape Changes on Data and Safety Monitoring Board Oversight of Clinical Trials. **2022**, 1, 1

8 Etiology of Stroke Subtypes. **1991**, 26, 943-956 0

7 Suprachoroidal Hemorrhage after XEN Gel Implant Requiring Surgical Drainage. **2022**, 16, 132-135 0

6 Stroke Prevention in Atrial Fibrillation. 0

5 PREDICTION OF THROMBOEMBOLISM IN PATIENTS WITH LONG-LASTING ATRIAL FIBRILLATION. **2014**, 90-94 0

4 Safety and feasibility of interventional left atrial appendage closure without contrast agent. **2018**, 4, 126-133 0

3 Prescribing Patterns of Direct-Acting Oral Anticoagulants in Patients With Atrial Fibrillation and Chronic Kidney Disease: A Retrospective Cohort Analysis. **2022**, 27, 107424842211422 0

2 Overestimation of anticoagulant benefit in patients with atrial fibrillation and low life expectancy: evidence from 12 randomized trials. 0

1 Contemporary Antiplatelet and Anticoagulant Therapies for Secondary Stroke Prevention: A Narrative Review of Current Literature and Guidelines. 0